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Both tobacco smoke and asbestos fibers enter the body mainly by 
inhalation. In the lungs, they may evoke oxidative stress, alter the 
protease-antiprotease balance, induce innate and adaptive immune 
responses, and create persistent inflammation leading eventually to 
lung injury. The type and severity of lung injury induced by foreign 
compounds varies greatly between individuals, even with similar 
exposure history. These differences are believed to originate from 
the complex interplay between genetic, epigenetic, environmental, 
and life course factors.
In this study, the effects of genetic variation on the risk and severity 
of asbestos and smoking related non-malignant pleural and pulmo-
nary changes and lung function impairment was examined among 
Finnish construction workers. The studied polymorphic genes 
encode proteins involved in xenobiotic metabolizing, proteolytic 
balance, inflammation, and innate immunity; pathways that are 
potentially linked to asbestos and tobacco smoke exposure. 
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3AbstRAct in Finnish  
– tiivistelMä
Asbestialtistuksen tiedetään aiheuttavan useita keuhkosairauksia, kuten 
keuhkokudoksen arpeutumista (keuhkofibroosi) ja keuhkopussin syöpää 
(mesoteliooma). Tarkkaa mekanismia, jolla asbestikuidut vaurioittavat 
keuhkoja, ei tunneta, mutta siihen uskotaan liittyvän reaktiivisten 
happiyhdisteiden, sytokiinien ja muiden tekijöiden välittämä jatkuva 
tulehdustila sekä epätasapaino keuhkojen tukikudosten proteiineja ha-
jottavien entsyymien ja niitä hillitsevien tekijöiden välillä. 
Tupakansavu sisältää happiradikaaleja ja tuhansia kemikaaleja, jotka 
voivat asbestin tavoin johtaa keuhkokudoksessa krooniseen tulehduk-
seen ja proteiini- ja DNA-tason muutoksiin. Tupakoinnin tiedetäänkin 
lisäävän keuhkosyövän ja useiden muiden syöpien riskiä ja altistavan 
myös keuhkoahtaumataudille (Chronic obstructive pulmonary disease; 
COPD) ja keuhkolaajentumalle (emfyseema).
Tässä väitöskirjatyössä tutkittiin useiden vierasaineiden muokkaami-
seen (EPHX1, GSTm1, GSTm3, GSTP1, GSTT1 ja NAT2), luonnolli-
seen immuniteettiin (NLRP3 ja CARD8), tulehdukseen (TNF, TGFB1 ja 
GC) ja tukikudosten hajottamiseen (mmP1, mmP9, mmP12, SERPI-
NE2 ja TImP2) liittyvien proteiinien geenien monimuotoisuuden mer-
kitystä hyvänlaatuisten keuhkomuutosten synnyssä. Tutkittavat geenit ja 
monimuotoisuuskohdat valittiin aiemman kirjallisuuden perusteella. Osa 
geenianalyyseista suoritettiin perinteisemmillä, geelielektroforeesiin ja 
entsyymirestriktioon perustuvilla erottelumenetelmillä, osa fluoresenssi- 
leimaukseen (Taqman) perustuvilla reaaliaikaisilla PCR-menetelmillä 
(kuoppalevy- ja siruformaatit) ja osa lusiferaasi-valoreaktioon perustuvalla 
pyrosekvensointimenetelmällä. 
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Tutkimusaineisto koostui kahdesta otoksesta suomalaisia asbestille 
ja tupakansavulle altistuneita rakennustyöntekijöitä, joille oli tehty 
huolelliset kliiniset ja radiologiset tutkimukset; keuhkojen tilavuus- 
ja virtausmittaukset oli suoritettu spirometrialla, keuhkokudoksen 
kaasujenvaihtokyky oli mitattu diffuusiokapasiteettitutkimuksella ja 
keuhkopussin ja keuhkokudoksen muutokset oli määritetty korkean 
resoluution tietokonetomografialla (High resolution computed tomo-
graphy; HRCT). 
Tutkimuksessa havaittiin vierasaineiden muokkaamiseen osallistuvan 
GSTT1 entsyymin geenin puutoksen altistavan sekä vaikealle keuhko-
kudoksen fibroosille että emfyseemalle ja kaasujenvaihtokapasiteetin 
alenemiselle. Nämä yhteydet olivat tilastollisesti merkitseviä sekä koko 
tutkimuspopulaatiossa että molemmissa alkuperäisissä tutkimusotoksissa. 
Keuhkokudoksen fibroosille altistava muoto löydettiin lisäksi luonnol-
liseen immuunivasteeseen osallistuvan, nk. inflammasomikompleksin 
keskeisen osan, NLRP3:n, geenistä. Toisen kompleksin osan, CARD8:n 
geenin, tietty muoto taas liitettiin keuhkopussin plakkien paksuuteen.
Tulehdusvälittäjäaine TGFB1:n geenin tietyn muodon puolestaan 
havaittiin suojaavan keuhkopussin fibroosilta, ja tietty kahden geno-
tyypin yhdistelmä, haplotyyppi, yhdistettiin keuhkopussin plakkien 
kalkkeutumisasteeseen. 
Keuhkoemfyseeman kehittymiseen liittyviä muotoja löydettiin lisäksi 
SERPINE2, MMP9, TIMP2, TNF ja TGFB1 geeneistä. Proteiinien ha-
jottamista rajoittavan SERPINE2:n geenin tietyn muodon ja haplotyypin 
havaittiin altistavan panlobulaarisen emfyseematyypin kehittymiselle. 
Tämä yhteys oli merkitsevä sekä koko tutkimuspopulaatiossa että mo-
lemmissa tutkimusotoksissa erikseen. 
Proteiineja hajottavan mmP9:n ja tulehdussytokiini TGFB1:n 
geenin tiettyjen muotojen todettiin suojaavan sentrilobulaariselta, lä-
heisesti tupakointiin liittyvältä emfyseematyypiltä, kun taas proteiinien 
hajottamista säätelevän TImP2:n ja tulehdussytokiini TNF:n geenin 
tiettyjen muotojen havaittiin lisäävän paraseptaalisen emfyseeman 
kehittymisen riskiä. TIMP2:n geenimuoto oli lisäksi yhteydessä FEV1/
FVC ja mEF50 keuhkotoimintamuuttujiin, joiden aleneminen viittaa 
emfyseemalle tyypilliseen pienten keuhkoputkien ahtautumiseen. Vie-
rasaineiden muokkaamiseen osallistuvan, emfyseemaan ja alentuneeseen 
keuhkotoimintaan aikaisemminkin liitetyn GSTm3:n geenin tietyn 
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muodon havaittiin niin ikään olevan yhteydessä FEV1/FVC ja mEF50 
keuhkotoimintamuuttujiin, joista mEF50 oli merkitsevästi alentunut 
kyseisen geenimuodon kantajilla. 
Löydösten perusteella vierasaineiden muokkaamiseen, tukikudosten 
hajottamiseen, luonnolliseen immuniteettiin ja tulehdukseen osallistu-
vien proteiinien perinnöllisellä muuntelulla on vaikutusta asbesti- ja 
tupakka-altistumiseen liittyvien emfyseema- ja fibroosimuutosten sekä 
keuhkotoiminnan häiriöiden kehittymiseen ja muutosten vaikeusastee-
seen. Lisäksi havainnot emfyseeman suhteen selventävät rakenteellisesti 
erilaisten emfyseematyyppien syntymiseen johtavia tekijöitä. Koska 
useimpien sairauksien taustalla vaikuttaa geneettisen muuntelun li-
säksi monia muitakin tekijöitä, geneettisen informaation ekspressio-, 
proteiini- ja metaboliatason muutoksiin yhdistävän systeemibiologisen 
lähestymistavan uskotaan tulevaisuudessa vievän lähemmäksi sairauksien 
syntymekanismien selviämistä, hoitoa ja ehkäisemistä.
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The adverse pulmonary effects of inhaling asbestos fibers are well char-
acterized; in addition to malignant diseases, they have been shown to 
promote the development of several non-malignant lesions of the lungs 
and pleura. Although the exact mechanisms by which the inhalation of 
asbestos fibers leads to lung tissue injury are still unclear, they may involve 
a persistent inflammatory response mediated by reactive oxygen species 
(ROS), cytokines, growth factors, and pro-inflammatory mediators, as 
well as changes in the proteolytic balance of the lungs. 
Inhalation of tobacco smoke exposes the lungs to thousands of 
chemicals many of which evoke oxidative stress, DNA-damage, chronic 
inflammation, and alterations in the protease-antiprotease balance. This, 
in turn, may induce carcinogenesis and promote the development of 
non-malignant disorders, such as chronic obstructive pulmonary disease 
(COPD) and emphysema. 
Since oxidative stress, inflammation, and proteolytic imbalance are 
potential consequences of exposures to both asbestos fibers and tobacco 
smoke, the proteins involved in these pathways have been implicated in 
the pathogenesis of lung diseases related to these exposures. moreover, 
genetic variations affecting the expression or functional properties of 
these proteins are believed to partly account for the inter-individual 
differences in morbidity and disease progression between patients with 
similar exposure histories.
In this work, role of several polymorphisms in genes encoding proteins 
involved in xenobiotic metabolism (EPHX1, GSTm1, GSTm3, GSTP1, 
GSTT1, and NAT2), protease-antiprotease balance (mmP1, mmP9, 
mmP12, SERPINE2, and TImP2), inflammation (TNF, TGFB1, and 
GC), and innate immunity (NLRP3 and CARD8) was examined in 
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relation to asbestos and smoking related non-malignant pleural and 
pulmonary changes in two clinically and radiologically examined cohorts 
of Finnish construction workers. The studied genes and polymorphisms 
were selected based on the published literature which indicated that they 
might be potential candidate modifiers of the abovementioned lung dis-
eases. Different sophisticated techniques were employed in the genotyp-
ing analysis including multiplex PCR, PCR-based restriction fragment 
length polymorphism (PCR-RFLP), pyrosequencing, Taqman® allelic 
discrimination, and OpenArray®.
The GSTT1 gene deletion was found to increase the risk for interstitial 
lung fibrosis, pulmonary emphysema, and decreased diffusing capacity for 
carbon monoxide (DLCO and DLCO/VA). These associations were signifi-
cant in the whole study population and in both of the study cohorts sepa-
rately. The risk for interstitial lung fibrosis was also found to be increased 
by a certain genotype of the innate immunity related NLRP3 gene, protein 
product of which is an important part of the NLRP3 inflammasome com-
plex. A truncating polymorphism in the gene of another member of the 
complex, CARD8, was found to be associated with the greatest thickness 
of pleural plaques. moreover, both a polymorphism and a haplotype of 
the inflammatory cytokine TGFB1 gene were found to be associated with 
visceral pleural fibrosis and calcification degree of pleural plaques. 
Polymorphisms associated with pulmonary emphysema were also 
found in SERPINE2, MMP9, TIMP2, TNF and TGFB1 genes. more-
over, a certain genotype and a haplotype in the serine protease inhibitor 
SERPINE2 gene were found to predispose to panlobular emphysema. 
These associations were significant in the whole study population and 
individually in both of the study cohorts. Genotypes in metalloproteinase 
MMP9 and inflammatory cytokine TGFB1 genes, on the other hand, 
were found to protect from centrilobular emphysema, disease type closely 
related to smoking. In addition, the risk for paraseptal emphysema was 
increased by certain genotype of metalloproteinase inhibitor TIMP2 and 
inflammatory cytokine TNF genes. 
The studied TIMP2 polymorphism was also associated to decreased 
FEV1/FVC and mEF50, indicative of peripheral obstruction typical 
of smoking related emphysema and COPD. Similarly, a promoter 
polymorphism in xenobiotic metabolizing enzyme GSTm3 gene was 
associated with FEV1/FVC-ratio and mEF50; stratified analysis revealed 
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significantly reduced mEF50 among individuals with certain GSTM3 
genotype. 
Our results indicate that polymorphisms of genes involved in xeno-
biotic metabolism, protease-antiprotease balance, inflammation, and 
innate immunity are important modifiers of the risk of developing non-
malignant pleural and pulmonary changes and lung function impairment 
related to asbestos and tobacco smoke exposure. The findings concerning 
emphysema also shed light on the etiology of different emphysema sub-
types. Due to the complex nature of biological systems, however, genetic 
variation is expected to define the disease course in concert with other 
factors such as epigenetic changes and life course events. The advent of a 
systems biology approach allows the integration of different “omics” and 
these factors and in the future, will hopefully increase the understanding 
of the human diseasome to a whole new level.
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1  intRoduction
The pulmonary effects of inhalation of asbestos fibers are well character-
ized; they are known not only to increase the risk for bronchogenic carci-
noma and malignant mesothelioma, but also to promote the development 
of several non-malignant lesions of the lungs and the pleura [1]. Despite 
the current national bans and restrictions, asbestos induced pulmonary 
and pleural diseases still represent a significant health concern due to the 
huge amounts of asbestos that have been mined and used in different 
insulating and construction purposes since the early 1900s, combined 
with the long latency period of most asbestos associated conditions [2]. 
Tobacco smoke, which is known to contain thousands of harm-
ful chemicals, is also a major source of subjective and environmental 
exposure and a truly global health burden being responsible for several 
millions of deaths yearly all around the world [3]. In addition to caus-
ing lung cancer, tobacco smoke has been shown to increase the risk for 
other malignancies and promote the development of cardiovascular and 
respiratory disorders [4–6]. 
Both tobacco smoke and asbestos fibers can trigger the release of oxy-
gen radicals, proteolytic enzymes and toxic mediators by interacting with 
inflammatory and other target cells [7, 8]. In the lungs, free radicals and 
foreign compounds are inactivated by different antioxidants and groups 
of xenobiotic metabolizing enzymes (XmEs) intended to detoxify and 
eliminate these harmful agents [9, 10]. Nonetheless, even though there 
are effective defense mechanisms, these agents may still induce oxidative 
stress, alter the protease-antiprotease balance, induce innate and adaptive 
immune responses, and lead to the presence of persistent inflammation 
eventually causing a lung injury [11, 12].
Although asbestos exposure and tobacco smoke play an important 
role in the development of several lung diseases, there is huge variation 
16
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in morbidity, disease progression, and clinical manifestations between 
individuals with similar exposure histories. This variation is believed 
to originate from individual susceptibilities, which in turn are due to 
genetic (alterations in DNA sequence) and/or epigenetic (modifications 
of DNA that do not alter the sequence) variation, life course events, and 
ultimately to the complex interplay between the environment and these 
factors [13].
In this thesis, the effects of genetic variation on the risk and severity 
of asbestos and smoking related non-malignant pleural and pulmonary 
changes and lung function impairment were examined in Finnish con-
struction workers. The studied polymorphic genes encode for proteins 
involved in several pathways potentially linked to asbestos and tobacco 
smoke exposure: xenobiotic metabolism (EPHX1, GSTm1, GSTm3, 
GSTP1, GSTT1, and NAT2), proteolytic balance (mmP1, mmP9, 
mmP12, SERPINE2, and TImP2), inflammation (TNF, TGFB1, and 
GC), and innate immunity (NLRP3 and CARD8).
17
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2.1  Asbestos and the lungs
2.1.1  characteristics and use of asbestos
The term asbestos refers to a group of naturally occurring fibrous silicate 
minerals utilized in many industrial applications because of their ther-
mochemical and electrical resistance, high tensile strength, and flexibility. 
There are several commercially used, chemically and physically different 
asbestos types, e.g., the serpentine mineral, chrysotile (white asbestos), 
and the amphibole minerals; crocidolite (blue asbestos), amosite (brown 
asbestos), anthophyllite, tremolite, and actinolite [14]. 
Chrysotile fibers are extremely thin and flexible; they are composed 
of hydrated, magnesium-containing phyllosilicate-sheets that have been 
rolled up to form hollow cylinders. Bundles of chrysotile fibers can have 
variable length and are often curvilinear. The amphibole minerals are 
needle-like, crystalline structures typically less hydrated and less flexible 
than the chrysotile fibers. The core structures of amphiboles amosite 
and crocidolite contain a considerable amount (27–30%) of iron that 
can be redox activated, whereas in chrysotile a smaller portion (1–6%) 
of redox-active iron is located on the surface of the mineral [14, 15].
Asbestos has been used all around the world for more than 3000 
years in thousands of products, such as textiles, plastics, cement prod-
ucts, brakes, engine gaskets and insulation for boilers, steam pipes, and 
electrical wiring. Asbestos usage peaked in the middle of the 1970s, 
when 4.8 megatons of asbestos were produced and used in industrial 
applications [16]. As the health hazards of asbestos became to emerge, 
the demand for asbestos started to decline in the United States as well 
as in many European countries. 
18
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Worldwide, most of the commercially consumed asbestos type (< 
90%) has been chrysotile, followed by crocidolite, amosite, and antho-
phyllite [16]. In Finland, however, approximately 40% of all the asbestos 
used has been anthophyllite due to its domestic production: a total of 
350 000 tons of anthophyllite were mined in Paakkila between 1918 and 
1975 [17]. It has also been estimated that over 200 000 Finnish work-
ers have been exposed to asbestos, and that more than 200 000 tons of 
asbestos are still to be found in hundreds of thousands of buildings [18]. 
In Finland, asbestos spraying was forbidden in 1976 and a complete 
asbestos ban was introduced in 1994 (Finnish Government decision 
1380/1994). Subsequently, 54 other countries have banned or restricted 
the use of asbestos [19]. Nonetheless, the global use of asbestos has 
remained rather stable during 2003–2007, the main consumers being 
China, India, and Russia [20].
2.1.2  Mechanisms of injury
Although asbestos can enter the body also via skin contact and ingestion, 
it is the inhalation of fibers that is essentially responsible for all present 
asbestos-related adverse health effects [21]. The toxicity of inhaled asbes-
tos depends on multiple factors, e.g., the physical and chemical properties 
of the mineral since they will affect the biodurability and surface reactivity 
of the fiber, cumulative dose, time that has been elapsed since the initial 
exposure, and genetic background of the host [7, 11]. 
Chrysotile has greatly reduced biopersistence compared to the amphi-
boles; the soluble magnesium molecules on the outside of the chrysotile 
structures promote the breakdown of the fibers in the lung tissue, and the 
clearance of inhaled chrysotile can occur within a period of few weeks. 
The amphiboles, in contrast, are generally more resistant to fragmenta-
tion and degradation in the lungs and their biological clearance is usually 
measured in decades [7, 14].
Once inhaled and having reached the alveolar region, the asbestos 
fibers are surrounded and internalized by alveolar macrophages (Am), 
which triggers an inflammatory reaction and the release of reactive oxygen 
species (ROS) from the activated Ams. However, the longer fibers cannot 
be completely engulfed by the macrophages, and so called “frustrated 
phagocytosis” takes place. This leads to the formation of asbestos bodies, 
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fibers coated with mucopolysaccharides and iron-rich proteins (see Figure 
1), alongside with the release of cytokines and growth factors and the 
generation of ROS and reactive nitrogen species (RNS) [2, 11]. There 
is recent evidence suggesting that ROS can also be generated from the 
mitochondria of inflammatory and other target cells, such as alveolar 
epithelial cells (AECs) [22, 23]. Another source of ROS and RNS fol-
lowing asbestos exposure is the reactions occurring on the surface of 
the mineral fibers, which are mainly attributed to the presence of redox 
active iron [24, 25].
Figure 1. Papanicolaou-stained bronchial sample with asbestos-body inside 
a macrophage. Picture from the archive of Finnish Institute of Occupational 
Health by courtesy of Sauli Savukoski.
ROS and RNS are considered as important mediators of the carcino-
genicity and toxicity of asbestos fibers since these radicals can induce 
DNA-damage and activate several signaling pathways leading to cell 
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proliferation, cell death, and inflammation [26]. The combination of 
DNA-damage and ROS can induce apoptosis of AECs, which seems to 
be an important factor for myofibroblast differentiation, collagen deposi-
tion, and ultimately for the development of pulmonary fibrosis [11, 27]. 
Asbestos and silica can also activate NLRP3 inflammasome complex 
through fiber phagocytosis and ROS originating from the mitochondria 
[28–30]. Activation of the NLRP3 complex leads to increased interleukin 
1β (IL-1β) production and an inflammatory response, and this may be 
an important mediator of asbestos-related fibrosis and cancers. Asbestos 
has also been shown to alter the expression of tumor suppressor p53, a 
protein which has been implicated in the pathophysiology of pulmonary 
fibrosis and asbestos associated malignancies [31–33].
Growth factors and cytokines released from phagocytic macrophages 
include platelet derived growth factor (PDGF), transforming growth 
factor β (TGFB1), and tumor necrosis factor α (TNF). PDGF stimu-
lates fibroblasts to migrate and proliferate, and subsequently TGFB1 
activates them to produce collagen and other matrix proteins [34]. 
TNF, on the other hand, regulates TGFB1 production. Together these 
signaling molecules can trigger a fibrogenic response after the exposure 
to asbestos fibers [26]. 
Tobacco smoke has been shown to amplify the toxic effects of asbestos, 
promoting the development of asbestos-associated diseases [35]. It seems 
that at least in the case of lung cancer, the relationship between these 
exposures is synergistic [36]. This has been speculated to be due to the 
impaired clearance of asbestos from the lungs of smokers, i.e., smokers 
have an increased fiber burden [37].
2.1.3  non-malignant disorders associated with 
asbestos exposure
In addition to bronchogenic carcinoma and malignant mesothelioma 
(which were not topics of this thesis), asbestos is known to promote 
the development of several non-malignant lesions of the lungs and the 
pleura [1].
Asbestosis refers to interstitial lung fibrosis caused by the inhalation 
and deposition of asbestos fibers in the lungs. It is characterized by the 
accumulation of the extracellular matrix (ECm) and inflammatory cells 
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in the alveolar interstitial tissue. Asbestosis is usually associated with dysp-
nea, dry cough, bilateral crackles on auscultation, and changes in lung 
function [38]. Although restrictive impairment and decreased diffusing 
capacity are typical among asbestosis patients [39], mixed restrictive-
obstructive pattern may also be observed [38]. 
Asbestosis resembles closely some other inflammatory and fibrotic 
lung disorders such as idiopathic pulmonary fibrosis (IPF), which com-
plicates diagnosis. Although a chest radiograph showing the characteristic 
signs of asbestosis in the presence of an appropriate exposure history 
has previously been considered as adequate to allow the diagnosis of the 
disease [38], high resolution computed tomography (HRCT) is a more 
sensitive and specific technique for revealing the parenchymal and pleural 
changes which are characteristic of asbestosis and asbestos exposure [40, 
41]. The typical HRCT findings in asbestosis include subpleural dot-
like or curvilinear opacities, interlobular septal thickening, parenchymal 
bands, and in more advanced fibrosis, honeycombing (see figure 2) [42]. 
Figure 3 shows a CT image from a patient with massive fibrosis. 
Figure 2. HRCT findings associated to asbestosis and emphysema. Modified 
from [43].
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Figure 3. Massive fibrosis in both lungs of an asbestosis patient. Picture from 
the archive of Finnish Institute of Occupational Health by courtesy of Tapio 
Vehmas.
Asbestos exposure may also result in a thickening of the pleura due to 
collagen deposition. This thickening can be widespread diffuse fibrosis, 
extending from the visceral to the parietal pleura or parenchyma, or it can 
occur as discrete plaques limited to the parietal pleura [21]. The thickened 
visceral pleura may also fold to form rounded atelectasis. Circumscribed 
plaques are usually bilateral and may calcify over time. They are the most 
common manifestation of the inhalation of asbestos, but rarely occur in 
a timespan of less than 20 years from the initial exposure [38]. 
HRCT is very useful in detecting pleural plaques and distinguishing 
them from extra-pleural fat [38, 44]. Although pleural plaques are con-
sidered as relatively innocuous, they may be associated with a restrictive 
ventilator pattern, the clinical significance of which is unknown [39, 45]. 
The number and extent of pleural plaques have also been associated with 
coronary heart disease and increased all-cause mortality [46–48]. Figure 4 
shows a CT image from a patient with calcified bilateral pleural plaques.
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Figure 4. Calcified bilateral pleural plaques. Picture from the archive of Finn-
ish Institute of Occupational Health by courtesy of Tapio Vehmas.
2.2 tobacco smoke and the lungs
Tobacco smoking is a major source of environmental exposure and a huge 
global health burden. Worldwide, approximately 43% of men and 10% 
of women smoke, and it has been estimated that tobacco is responsible 
for over 5 million deaths yearly [3]. Cancer is one of the main causes of 
death in smokers, and approximately 90% of lung cancers are attribut-
able to smoking [4]. In addition, the risks of respiratory tract, urinary 
bladder, pancreas, kidney, stomach, liver, esophagus, bone marrow, and 
cervix cancers are all increased in smokers. Aside from malignancies, 
tobacco smoke is an essential promoter of cardiovascular and chronic 
respiratory diseases [5, 6].
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2.2.1  biotransformation of tobacco smoke 
compounds
Tobacco smoke is a complex mixture of over 5000 chemical compounds, 
including carcinogens such as polyaromatic hydrocarbons (PAHs), N-
nitrosamines, aromatic amines, and benzene, as well as co-carcinogens, 
tumor promoters, toxicants, irritants, free radicals, and inflammatory 
agents [6, 49]. The inhalation of tobacco smoke exposes the respiratory 
tract to these agents making it the primary target site for their toxic effects. 
In the lungs, as well as in other organs, most foreign compounds 
(i.e., the xenobiotics) are metabolized by phase I and phase II enzymes 
intending ultimately to achieve detoxification and elimination of the 
xenobiotic [9]. A schematic presentation illustrating the metabolism of 
xenobiotic compounds is shown in Figure 5. 
XENOBIOTIC 
Lipophilic Polar Hydrophilic Highly 
lipophilic 
Accumulation 
PHASE I metabolism 
Cytochrome P450 (CYP450), flavin containing 
mono-oxygenases (FMOs), monoamine oxidase 
(MAO), xanthine oxidase/aldehyde oxidase (XO/
AO), cytochrome P450 reductase (CPR), Alcohol 
dehydrogenase (ADH)   
PHASE II metabolism 
UDP-glucuronosyltransferases (UGTs), 
sulfotransferases (SULTs), glutathione S-
transferases (GSTs),  N-acetyltransferases 
(NATs), NAD[P]H:Quinone – oxidoreductase, 
epoxide hydrolases (EPHXs) 
Renal excretion Biliary excretion 
Lipophilic Polar 
Figure 5. Schematic presentation of the metabolism of xenobiotics. Figure 
based on [9, 50].
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Phase I enzymes include the cytochrome P450 (CYP) superfamily, fla-
vin containing mono-oxygenases (FmOs), monoamine oxidase (mAO), 
and xanthine oxidase/aldehyde oxidase (XO/AO). Phase I reactions, 
such as oxidation, epoxidation and dehydrogenation, can introduce or 
unmask a functional group and this can even lead to bioactivation of an 
inactive compound. These potentially active and/or toxic metabolites are 
then modified by phase II metabolizing or conjugating enzymes, such 
as UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs), 
glutathione S-transferases (GSTs), epoxide hydrolases (EPHXs), and 
N-acetyltransferases (NATs). Phase II reactions generally result in the 
deactivation of the toxic compound as well as an increase in its hy-
drophilicity thereby facilitating its excretion from the body [50]. The 
expression of phase I and II enzymes may be enhanced by the exposure 
to toxic agents [51].
2.2.2  oxidative stress
Tobacco smoke is an plentiful source of oxidants; the gaseous phase 
alone contains approximately 1015 radicals per puff, mostly short-lived 
oxidants such as superoxide anion (O2
-) and nitric oxide (NO), the 
latter of which reacts quickly to form peroxynitrite. The water-soluble 
tar phase contains more stable and organic radicals, such as phenol and 
semiquinone radicals, which can react with O2
- to form the hydroxyl 
radical (.OH) and hydrogen peroxide (H2O2) [52, 53]. In addition to 
the exposure to these toxic compounds in the smoke, reactive oxidants 
can arise endogenously from inflammatory, epithelial, endothelial, and 
mesenchymal cells within tissues [54]. 
The amount of oxidants in the lungs is normally controlled by the 
many antioxidant defense mechanisms which are present in pulmonary 
tissue, e.g., glutathione (GSH), GSH peroxidase, catalases, and super-
oxide dismutases (SODs) [10]. Oxidants in tobacco smoke can activate 
the nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription 
factor which regulates the expression of many genes involved in the 
antioxidant response [55]. A shift from the antioxidant balance in favor 
of the oxidants creates oxidative stress [56]. Excess ROS, in turn, can 
evoke direct damage on DNA, proteins, lipids, and other components 
of the lung matrix, interfere with elastin synthesis and repair, inactivate 
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anti-proteases and activate proteases leading to a proteolytic imbalance, 
and trigger different inflammatory pathways [57, 58]. These adverse 
effects of oxidative stress are involved in the development of tobacco 
smoke associated malignancies as well as non-malignant lung diseases 
such as asthma, chronic obstructive pulmonary disease (COPD), and 
lung fibrosis [59–61].
2.2.3  Inflammatory response
The airways and lungs have evolved effective host defense mechanisms 
against pathogenic microbes and other environmental agents. These 
include innate defense mechanism, such as the epithelial lining, muco-
ciliary clearance, and cells that participate in innate immunity, as well 
as adaptive immune mechanisms [62]. 
The inhalation of tobacco smoke triggers an inflammatory response 
involving both innate and adaptive immune systems. This is character-
ized by recruitment of different inflammatory cells, such as neutrophils, 
macrophages and lymphocytes, into the lungs and by the release of 
numerous pro-inflammatory cytokines including TNF, IL-1, IL-6, and 
IL-8 [8, 58]. Figure 6 illustrates the effects of tobacco smoke leading to 
inflammation and lung injury.
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Figure 6. Simplified illustration on the effects of smoking leading to inflam-
mation and lung injury. Modified from [63, 64].
Under normal conditions, the integrity of the tight junctions provides a 
barrier to airway epithelium by restricting the penetration of exogenous 
particles into the airway interstitium. The reactive components of tobacco 
smoke produce direct injuries, resulting in increased mucosal perme-
ability. This is further reinforced by the ROS and other endogenous 
mediators released by the inflammatory cells [8]. Some of the normally 
intracellular molecules released after cellular damage can serve as danger-
associated molecular patterns (DAmPs) which are identified by pattern 
recognition receptors (PRRs), such as Toll-like receptors (TLRs) 4 and 2. 
These receptors may activate the NLRP3 inflammasome complex lead-
ing to increased IL-1β production and the generation of a non-specific 
inflammatory response [65]. 
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The tobacco smoke induced injury also increases the number of 
macrophages and neutrophils [66], and stimulates the release of poly-
morphonuclear leukocytes (PmNs) from the bone marrow, followed 
by their accumulation into the lung microvasculature [67, 68]. These 
leukocytes then become attached to the endothelial cells of the vessels 
and are eventually able to enter the lungs due to the presence of airway 
irritation and injury. The attachment and penetration of inflammatory 
cells into the lungs is not completely understood, but is likely to be 
mediated via TNF and IL-1, which induce the expression of adhesion 
molecules, and IL-8, which serves as a chemoattractant to allow these cells 
to penetrate into the lungs [8]. The release of cytokines from epithelial 
and inflammatory cells is triggered by the activation of the transcription 
factor NFκB [66]. NFκB, a factor which can be activated by oxidative 
stress, seems to be an important regulator of tobacco smoke induced 
inflammation and lung tissue injury [8, 66].
Dendritic cells (DCs) link the innate and adaptive immune responses 
by capturing antigens released from damaged tissues and incoming 
pathogens and presenting them to naïve T-cells in the draining lymph 
nodes [69]. As a response to these antigens and other microenvironmental 
factors, T helper (Th) cells develop and differentiate into Th1, Th2, or 
Th17 cells [70]. Although Th1 and Th17 type inflammation has been 
associated with COPD and the Th2 type response with asthma, the role 
of tobacco smoke in T-cell balance remains controversial [8]. 
Tobacco smoke has also been associated with the development of 
several autoimmune diseases, such as rheumatoid arthritis and systemic 
lupus erythematosus. The exact mechanisms by which tobacco smoke 
contributes to autoimmunity have not yet been resolved [58]. 
2.2.4  smoking related lung diseases:  
coPd and emphysema
COPD is a progressive, heterogeneous disorder characterized by inflam-
mation of the airways, irreversible airway obstruction, and systemic ef-
fects [71, 72]. The typical pulmonary manifestations of COPD include 
chronic bronchitis, small airways disease, and emphysema, but it is also 
associated with severe extrapulmonary comorbidities such as cardiovascu-
lar disease, metabolic syndrome, skeletal muscle wasting, and osteoporosis 
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[73, 74]. Smoking is the main risk factor for COPD and it has been 
estimated that 15–20% of smokers will develop the disease [75, 76], 
although this value has been claimed to be an underestimation [77, 78]. 
At the structural level, the pulmonary changes related to COPD 
involve the central and peripheral airways, lung parenchyma, and the 
pulmonary vasculature [71]. The involvement of these compartments and 
the associated comorbidities, however, varies greatly between patients, 
and this reflects the heterogeneity of the disease. Currently, COPD is 
diagnosed based on the relevant symptoms (cough, sputum production, 
or dyspnea), history of exposure to the risk factors of the disease, and the 
presence of airflow obstruction (post-bronchodilator FEV1/FVC ratio < 
0.7) [79]. During recent years, the need for phenotyping the suspected 
COPD-patients has become evident [80, 81]. 
The destruction of the lung parenchyma is commonly referred to as 
pulmonary emphysema [82]. Emphysema is characterized by a progres-
sive loss of alveoli, the gas-exchanging units of the lung, and a reduction 
in the pulmonary capillary bed resulting in marked airspace enlargement, 
reduced pulmonary circulation, and the loss of elastic recoil in the lungs 
[83]. Smoking associated emphysema can be classified into three ma-
jor subtypes based on the morphology and anatomical distribution of 
the areas of lung destruction: centrilobular, paraseptal, and panlobular 
emphysema (see Figure 2) [84]. The extent and severity of the tissue 
destruction as well as the type of emphysema can be reliably detected 
with HRCT [82, 85]. 
Centrilobular (centriacinar) emphysema is the most common type 
of emphysema and closely associated to tobacco smoking [86, 87]. It is 
characterized by an enlargement of the centriacinar airspace, affecting 
mainly the proximal respiratory bronchioles. Centrilobular emphysema 
is predominantly distributed in the upper lung zones [88]. Paraseptal 
(distal acinar) emphysema involves the alveolar ducts and sacs in the 
subpleural regions adjacent to the interlobular septa [84]. It is commonly 
located in the dorsal surface of the upper lung, and may coexist with 
fibrosis and/or other emphysema types [89]. Figure 7 shows a CT image 
from a patient with extensive paraseptal and centrilobular emphysema.
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Figure 7. Centrilobular emphysema with extensive paraseptal emphysema 
in subpleural areas. Picture from the archive of Finnish Institute of Occupa-
tional Health by courtesy of Tapio Vehmas.
Panlobular (panacinar) emphysema involves the entire pulmonary lobule 
with a uniform dilatation of the air space from the respiratory bronchioles 
to the alveoli [88]. It is often distributed in the lower lung zones [84]. 
The bullae are sharply delineated areas of emphysema, at least 1 cm in 
diameter [90]. These structures can develop in association with any type 
of emphysema, but are most commonly seen with centrilobular and 
paraseptal disease. The term bullous emphysema is sometimes used when 
bullae become large enough to interfere with the respiratory function [88]. 
The airflow limitation characteristics of COPD results from thicken-
ing of the small airways and mucus plugging in the small conducting 
airways [91], promoted by peribronchiolar fibrosis, thus narrowing the 
lumen of bronchi and bronchioles [92]. The emphysematous destruction 
further contributes to a reduction in the expiratory flow affecting also 
the gas transfer capacity of the lungs [93, 94].
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The abnormal regulation of the inflammatory response induced by 
tobacco smoke and/or other environmental pollutants is considered as 
a key mediator in the development of COPD and emphysema [12]. 
The inflammatory response has been shown to be enhanced in COPD 
patients and to persist even after smoking cessation [95]. In addition to 
chronic inflammation, alterations in cellular repair, apoptosis, protease-
antiprotease balance, and oxidative stress have been implicated in the 
pathogenesis of COPD and emphysema [96, 97]. The exact mechanisms 
which lead to airway wall thickening and lung tissue destruction are 
not yet fully understood, but it is likely that they involve multifactorial 
processes interacting with genetic determinants [98, 99]. 
2.3  individual susceptibility to asbestos   
 and smoking related non-malignant   
 lung diseases
Although asbestos and tobacco smoke play an important role in the de-
velopment of various lung diseases, there is a great variation in morbidity, 
disease progression, and clinical manifestations between individuals with 
similar exposure histories. These differences are believed to originate from 
the complex interplay between genetic, epigenetic, and environmental 
factors [13].
2.3.1  Xenobiotic metabolizing enzyme genes
Since oxidative stress is a secondary effect from exposures to both as-
bestos fibers and tobacco smoke, genes involved in oxidative pathways 
are potential modifiers of the risk for developing lung diseases related to 
these exposures. The results from previous studies on GST, EPHX1, and 
NAT2 polymorphisms and asbestos related non-malignant lung diseases 
are summarized in Table 1, and those of the meta-analyses on GST and 
EPHX1 polymorphisms and COPD are shown in Table 2.
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GSTs consist of a superfamily of xenobiotic metabolizing enzymes 
involved in conjugation of glutathione with various electrophilic com-
pounds and products of oxidative stress. A widely studied member of the 
family, GSTm1, is involved in the metabolism of diol-epoxide derivatives 
of PAHs and ROS [114]. GSTT1, on the other hand, can detoxify meth-
ylating agents, pesticides and many chemicals present in cigarette smoke 
[115]. The GSTP1 enzyme, which is the most abundantly expressed GST 
in human lungs, shares some substrate specificity with GSTm1, and is 
active in metabolizing many epoxides of PAHs including benzo(a)pyrene 
[116]. GSTm3, another member of the GST-family participating in the 
metabolism of PAHs, is also expressed in the lungs [116, 117].
The GSTM1 null genotype leads to a complete lack of the enzyme 
activity. This gene deficiency has previously been connected to an in-
creased risk of COPD [118, 119], and recent meta-analyses have clearly 
confirmed this association (Table 2) [106, 108, 109, 113]. GSTM1 null 
genotype has also been shown to predispose smokers to emphysema and 
lung cancer [120], and to increase the risk for asbestos induced non-
malignant pulmonary diseases (Table 1) [101]. 
GSTT1 null genotype has also been extensively studied concerning 
COPD, but meta-analyses have revealed that it does not significantly af-
fect the risk of COPD (Table 2) [106, 108, 109, 113]. GSTT1 deficiency 
has, on the other hand, been shown to protect against the development of 
asbestosis (Table 1) [105], and an interaction with the GSTT1 deletion 
and smoking on lung function has also been observed [121].
In GSTM3, there are two functional polymorphisms, which are 
believed to affect the expression of the gene: a three-base pair deletion 
(*B allele) that results in the formation of a recognition sequence for 
transcription factor YY1, and a promoter polymorphism (A→C) located 
63 bp upstream the translation initiation site [122]. The expression level 
of GSTm3 has recently been associated with emphysema severity [123]. 
GSTP1 gene contains an amino acid changing polymorphism, 
Ile105Val, which has been shown to alter the catalytic activity of the 
enzyme [124, 125]. This polymorphism has been associated with 
asbestos-related pulmonary fibrosis, COPD, and impairment of lung 
function [126–128]. The results from a large meta-analysis indicated 
that GSTP1 Val-allele could be a risk factor for COPD in Caucasian 
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but protective against COPD among Asian populations (Table 2) [108]. 
Another meta-analysis confirmed the disadvantageous effect of Val-allele 
among Caucasians, but failed to confirm the protective influence among 
Asians [111]. The GSTP1 genotypes have also been associated to altered 
risk of CT defined emphysema [129].
NAT1 and NAT2 are involved in the metabolism of various xenobi-
otics including the aromatic and heterocyclic amines present in tobacco 
smoke and in the diet [130, 131]. The functional consequences of com-
mon NAT2 gene polymorphisms are well known, dividing the individu-
als into rapid and slow NAT2 acetylators [131]. Our research group 
has previously found an association between the NAT2 slow acetylator 
genotype and increased risk for both malignant (mesothelioma) and 
non-malignant (asbestosis and pleural plaques) pulmonary disorders in 
asbestos exposed workers (Table 1) [102, 132]. Polymorphisms affect-
ing the function of NAT2 have also been associated with COPD [133].
EPHX1 is a critical biotransformation enzyme that plays a dual role 
in the activation and detoxification of exogenous chemicals, such as 
epoxides and PAHs [134]. EPHX1 is expressed in most tissues and cell 
types, including the bronchial epithelium [135]. The EPHX1 activity 
has been shown to be altered by two common gene polymorphisms, 
Tyr113His and His139Arg, predicting slow or fast EPHX1 activity phe-
notype [136]. The slow activity His-alleles and the putative slow EPHX1 
activity phenotype have been associated with the development of COPD, 
emphysema, and impairment of lung function [118, 128, 137–143]. 
Other EPHX1 polymorphisms have been connected to COPD-related 
traits including emphysema distribution, airway wall phenotype, and 
cardiopulmonary exercise capacity (Table 3) [129, 142, 144]. 
The promoting effect of slow EPHX1 genotypes on the development 
of COPD could not be confirmed in two previous meta-analyses [108, 
109], while the most recent meta-analysis indicated that the risk for 
COPD might be marginally increased by the His-alleles in Caucasian 
populations [112]. Another earlier meta-analysis, on the other hand, 
implied that the His-allele in codon 113 might be a risk factor for COPD 
in Asian populations, and the putative very slow phenotype in Caucasian 
populations (Table 2) [107].
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2.3.2  Genes involved in protease-antiprotease 
balance pathway
The imbalance between proteases and antiproteases is a widely accepted 
mechanism behind the lung tissue destruction leading to pulmonary 
emphysema [152, 153]. This theory has been gaining support since 
the discovery of genetic variants causing low serum levels of the serine 
protease inhibitor Alpha-1-antitrypsin (AAT), which has been shown to 
predispose to early panlobular emphysema [154]. AAT, encoded by the 
SERPINA1 gene, has a major role in inactivating neutrophil elastase and 
other proteases thereby maintaining the protease-antiprotease balance 
and protecting lung tissue from destruction [155]. 
The gene of another member of the serpin-family, SERPINE2 (ser-
pin peptidase inhibitor, clade E [nexin, plasminogen activator inhibitor 
type 1] member 2) was identified as a COPD candidate gene in 2006 
by gene expression analysis from murine and human lung tissues [156]. 
The protein product of SERPINE2, also known as protease nexin 1 
(PN1), is mainly involved in coagulation and fibrinolysis with trypsin, 
thrombin, plasmin and urokinase as major substrates [157, 158]. In 
brain, it has been shown to control astrocyte proliferation and neurite 
outgrowth [159]. During recent years, the known functions of SER-
PINE2 has expanded, and a regulatory role has been proposed for it in 
cancer [160, 161].
In the first association study, several single nucleotide polymor-
phisms (SNPs) in SERPINE2 gene were associated to COPD in family 
and case-control -based study populations [156]. Subsequently, various 
replication attempts have produced rather contradictory results (Table 
4); the association between the SERPINE2 SNPs and COPD has been 
replicated in two large family and case-control -based Caucasian popula-
tions [162] and in two Asian populations [163, 164], but it was failed 
to be replicated in one Caucasian [165] and in two Asian populations 
[166, 167]. Recently, SERPINE2 SNPs have also been connected to 
pulmonary emphysema [129, 168].
In addition to the serine proteases, there are a number of proteolytic 
enzymes capable of degrading elastin and other matrix macromolecules, 
such as the matrix metalloproteinases (mmPs). Tissue inhibitors of 
metalloproteinases (TImPs), in turn, bind mmPs and inhibit their ac-
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tions [169]. mmPs and TImPs play an essential role in tissue repair and 
remodeling, and there is increasing evidence that some of them may be 
important in airway inflammation, and ultimately in the development 
of emphysema and fibrosis [153, 170, 171]. It has been shown that 
transgenic mice over-expressing mmP1 or mmP9 develop pulmonary 
changes comparable to human emphysema [172, 173], and that mice 
lacking the MMP12 gene are protected from emphysema despite the long 
term exposure to tobacco smoke [174]. Differential levels of mmP1, 
mmP9, mmP12, and TImP2, have also been detected in different 
fibrotic lung diseases [175, 176]. The previous association studies and 
meta-analyses concerning MMP1, MMP9, MMP12, and TIMP2 are 
shown in Tables 5 and 6, respectively.
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2.3.3  Inflammation and innate immunity  
–related genes
Asbestos is known to induce the production of IL-1β and TNF from 
alveolar macrophages, and these cytokines are believed to play an essen-
tial role in the early inflammatory response following asbestos exposure 
[195]. Furthermore, TNF enhances the expression of TGFB1 [196], 
which may lead to immune suppression and lung fibrogenesis [197, 
198]. Polymorphisms in both TNF and TGFB1 genes have previously 
been associated with the development of asbestosis [199, 200].
TNF and TGFB1 also participate in down-regulation of collagen 
degradation through mmPs and TImPs. Differences in the expression of 
TGFB1 and TNF cytokines have been shown to influence the pathogen-
esis of COPD in animal models, possibly via interactions with mmP9 
and mmP12 [201–203]. Genetic association studies have connected 
several polymorphisms and/or haplotypes of TGFB1 and TNF genes to 
the development of COPD [190, 204–206], and recent meta-analyses 
have confirmed some of these findings (Table 6) [108, 109, 190–193].
Asbestos-induced IL-1β secretion is mediated through the NLRP3 
inflammasome, which senses asbestos as a danger signal via the produced 
ROS [28]. The NLRP3 inflammasome -complex consists of several 
components, such as NLRP3, PYCARD, and CARD8 (also known as 
TUCAN), the genetic variation of which may affect the function of the 
complex. Certain polymorphisms in NLRP3 and CARD8 genes have been 
proposed to associate with IL-1β production and severe inflammation 
[207]. There are also animal studies indicating that NLRP3 could play 
a role in the development of asbestosis [28, 29].
GC (Group specific component; also known as Vitamin D-binding 
protein, VDBP) is a multifunctional serum protein, which participates 
in several immunologically important functions such as macrophage 
activation [208]. GC has been proposed to be involved in the chronic 
inflammation process of the lungs, and its gene polymorphisms have 
been extensively studied concerning several pulmonary disorders [209]. 
Certain GC polymorphisms have been associated with COPD (Table 7).
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2.3.4  Results from recent GWA studies
Genome-wide association (GWA) studies are being increasingly applied 
to identify the genetic determinants behind complex diseases. They are 
considered as an unbiased approach since tens, even hundreds of thou-
sands of markers are examined throughout the genome to locate areas 
associated to disease. In recent years, GWA studies have accelerated the 
discovery of potential candidate genes for several lung diseases [220]. 
The first GWA study concerning COPD identified and replicated two 
major susceptibility loci containing the CHRNA3 and CHRNA5 (cho-
linergic receptor, nicotinic, alpha 3/5), IREB2 (iron responsive element 
binding protein 2, involved in iron homeostasis) and HHIP (hedgehog 
interacting protein, known to have a role in lung development) genes 
[221]. The second GWA study confirmed these findings and identified 
a new locus containing the FAM13A gene (family with sequence simi-
larity 13, member A) [222]. Since then, a third COPD susceptibility 
locus harboring the RAB4 (RAB4A, member of RAS oncogene family), 
EGLN2 (C. Elegans homolog 2), MIA (melanoma inhibitory activity) 
and CYP2A6 (cytochrome P450, subfamily IIA, polypeptide 6) genes 
has been discovered [223]. 
Subsequently, the association of these COPD susceptibility genes 
was analyzed against different COPD phenotypes, and the CHRNA3/
CHRNA5 locus was found to be associated with increased smoking inten-
sity and HRCT-defined emphysema [224]. One GWA study conducted 
among COPD patients has also associated BICD1 gene (bicaudal D1) 
locus to CT-defined emphysema [225]. 
Several GWA studies have evaluated the genetic components of 
lung function with the HHIP locus being among the most commonly 
replicated genomic areas [226–228]. One large meta-analysis found 
also a locus containing the AGPHD1 (aminoglycide phosphotransferase 
domain containing protein 1), IREB2, and CHRNA3/CHRNA5 genes 
to be associated with airflow obstruction [229]. Another recent GWA 
study associated two chromosomal areas with a decline in lung func-
tion, and identified differential expression of three genes, TMEM26 
(transmembrane protein 26), ANK3 (ankyrin 3), and FOXA1 (forkhead 
box A1), residing in close vicinity to the associated SNPs [230]. Other 
genes, including TNS1 (tensin 1), GSTCD (glutathione S-transferase, 
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C-terminal domain containing), AGER (advanced glycosylation end 
product-specific receptor), HTR4 (5-hydroxytryptamine [serotonin] 
receptor 4), THSD4 (thrombospondin, type I, domain containing 4), 
DNER (delta/notch-like EGF-related receptor), SOX9 (SRY-box contain-
ing gene 9), and HLA-DQ (major histocompatibility complex, class II, 
DQ alpha chain) genes have also been implicated in GWA studies on 
different lung function measures [228, 231]. 
To date, no GWA studies have been conducted investigating inter-
stitial lung fibrosis or other asbestos associated non-malignant diseases. 
Instead, polymorphisms in MUC5B (mucin 5B) and TERT (telomerase 
reverse transcriptase) genes have been connected to idiopathic interstitial 
pneumonia (IIP) and idiopathic pulmonary fibrosis (IPF) in experiments 
using genome-wide applications [232, 233]. These associations have been 
replicated in another recent GWA study, which also found several novel 
IIP-associated loci, including FAM13A [234].
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The main objective of this thesis was to examine the role of several gene 
polymorphisms in the development of asbestos and tobacco smoke 
related non-malignant pleural and pulmonary changes among Finnish 
construction workers. more specifically, the studied polymorphisms 
were selected from genes involved in xenobiotic metabolism (EPHX1, 
GSTM1, GSTM3, GSTP1, GSTT1, and NAT2), protease-antiprotease 
balance (MMP1, MMP9, MMP12, SERPINE2, and TIMP2), inflam-
mation (TNF, TGFB1, and GC), and innate immunity (NLRP3 and 
CARD8), and their role examined in the development and severity of:
•	 asbestos related fibrotic changes in the visceral pleura and lung 
interstitium
•	 tobacco smoke related emphysematous changes of four subtypes 
(centrilobular, paraseptal, panlobular, and bullae), and
•	 impairment of lung function (FEV1, FVC, FEV1/FVC, mEF50, 
and TLC) and diffusing capacity (DLCO and DLCO/VA).
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4.1  study populations
4.1.1  Finnish construction workers
This study combines data from two previous screening studies. The first 
study group (ASBE, n = 602) was recruited in 1996–1997 and consisted 
of asbestos exposed subjects who lived in the Helsinki area, had asbestosis 
or asbestos-related pleural plaques, and had a positive smoking history 
[235, 236]. The second study group (ASSE, n = 633) was recruited 
in 2003–2004 and consisted of asbestos exposed subjects from three 
geographic areas (Helsinki, Tampere, Turku), who had previously been 
diagnosed with an asbestos related occupational disease or had visited 
the clinics of occupational medicine in Helsinki, Turku, or Tampere for 
a clinical follow-up [237]. 
Altogether 178 of the subjects recruited in 2003–2004 had already 
participated in the first study. They were therefore excluded from the 
second patient group in the present study before combining of the 
data. In the combined study population, blood samples were avail-
able for 1021 subjects, five of whom were excluded because of missing 
background information. Thus, the final study population consisted of 
1016 construction workers. In addition, the number of subjects in a 
particular study or analysis varied according to the number of successful 
genotyping analyses, the coverage of the clinical variable studied, and 
the confounders being used. Selected characteristics of the construction 
workers are shown in Table 8.
An approval for the study was obtained from the Ethical Commit-
tee of the Finnish Institute of Occupational Health (1995) and Ethics 
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Committee for Research in Occupational Health and Safety, Hospital 
District of Helsinki and Uusimaa (2003) according to the legislation 
at the time of the original study. All subjects gave informed consent to 
participate in the study.
Table 8. Selected characteristics of the construction workers.
Mean (SD) or N (%)
Age, years 63.3 (7.3)
Male sex 1000 (98.4%)
Smoking history
Never smoker 145 (14.3%)
Ex-smoker 638 (62.8%)
Current smoker 233 (20.7%)
Pack years of smoking (n = 996) 20.4 (16.9)
Years of asbestos exposure (n = 969) 23.9 (10.8)
Emphysema score (n = 3721) 2.00 (2.36)
Centrilobular (n = 240) 1.26 (1.02)
Paraseptal (n = 181) 1.00 (0.89)
Panlobular (n = 172) 0.96 (0.88)
Bullae (n = 131) 0.70 (0.75)
Interstitial lung fibrosis (n = 7921) 0.93 (0.66)
Visceral pleural fibrosis (n = 998) 135 (13.5%)
Pleural plaques
Greatest thickness (n = 1012) 1.87 (0.67)
Extent, cm2 (n = 1012) 103.1 (72.4)
Calcification (n = 1004) 1.37 (0.94)
Lung function2
FEV1 (n = 985) 83.8 (18.5)
FVC (n = 981) 89.3 (15.7)
FEV1/FVC ratio (n = 925) 93.8 (12.4)
MEF50 (n = 983) 66.3 (29.6)
TLC (n = 965) 87.3 (13.4)
DLCO (n = 970) 90.1 (20.1)
DLCO/VA (n = 972) 98.2 (18.4)
n = 1016 except as noted
1Subjects with radiologic score > 0
2Percent of Finnish reference values [238]
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4.1.2  Finnish population controls
In papers I and II, a demographic reference group was used in order to see 
whether the genotype frequencies in the case group differed from those in the 
general Finnish population. The recruitment of the demographic referents 
has been described in detail previously [239]. Briefly, the reference group 
consisted of 2155 Finnish Caucasians recruited from a health examination 
survey conducted by the Social Insurance Institution of Finland, Research 
and Development Centre. A random list, based on a population register was 
used to contact subjects living in south-western Finland. The recruitment 
system aimed at obtaining roughly equal numbers of subjects of both sexes 
in each of the five age strata. The age groups ending with seven (27-, 37-, 
47-, 57-, and 67-years) were chosen in order to prevent the examination 
from coinciding with other health examinations usually organized at ages 
ending with zero or five. Forty-nine referents were excluded because they 
had been diagnosed with some form of malignant disease and one because 
of missing background information. Thus, the final demographic reference 
group consisted of 2105 subjects (1051 males and 1054 females). Selected 
characteristics of the demographic references are shown in Table 9.
Unfortunately, since neither asbestos exposure history nor clinical 
data were available for the population controls and since detailed data on 
smoking was obtained only from the current smokers, this group could 
only be used as demographic referents and not as a reference group in 
the statistical analyses.
Table 9. Selected characteristics of 
demographic referents.
Mean (SD) or N (%)
Age, years 46.9 (14.0)
Male sex 1051 (49.9%)
Smoking history
Never smoker 981 (46.6%)
Ex-smoker 506 (24.0%)
Occasional 133 (6.3%)
Current smoker 485 (23.0%)
Pack years1 21.4 (19.4)
1For current smokers only
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4.2  Patient characterization
4.2.1  exposure assessment
The ASBE-participants were personally interviewed by an occupational 
physician with a standardised questionnaire including questions on smok-
ing habits and occupational history. They were construction workers who 
had installed heat and fire insulation or asbestos-containing walls and 
ceiling panels, used asbestos paints, putties and fillers, dismantled asbestos-
containing materials, or cleaned areas where asbestos was present. The 
mean years of asbestos exposure among ASBE-participants was 26.1±9.7, 
and mean pack-years 23.7±15.0. most of them were ex-smokers (70%) or 
current smokers (27%), and only 3% of them had never smoked.
The ASSE-participants filled in a self-administered questionnaire 
modified from the Finnish Environment and Asthma Study Question-
naire [240]. The final questionnaire included questions on demographic 
characteristics, respiratory symptoms and diseases, smoking exposure, 
and occupational exposures with the focus on asbestos. most of the 
ASSE-participants were construction workers, such as industrial, real 
estate and cleaning workers, or plumbers. The mean years of asbestos 
exposure among ASSE-participants was 20.8±11.4, and mean pack-years 
16.1±18.2. most of them were ex-smokers (54%) or current smokers 
(17%), and 29% of them had never smoked.
4.2.2 Radiological examinations
The lungs of the construction workers were imaged when they were 
prone in full inspiration with four different scanners: in 1996–1997 
the Picker PO 2000 (Picker International, Cleveland, USA) device 
was used, whereas in 2003–2004 Siemens Somatom Balance (Siemens 
medical, Erlangen, Germany) was used in Helsinki, Siemens Somatom 
Plus 4 (Siemens medical) was used in Tampere, and GE Light-speed 16 
Advantage (GE Healthcare, milwaukee, WI, USA) was used in Turku. 
The HRCT images were printed as hard copies and analyzed blindly by 
two radiologists in consensus (ASSE 2003–2004), or by three radiolo-
gists separately (ASBE 1996–1997). In the latter case, average values 
were used in the analysis.
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The radiologists scored visually the signs of interstitial lung fibrosis 
by using an arbitrary semiquantitative scale from 0 to 5 including one 
subclass between each class: 0 (normal finding), 1 (subnormal finding), 
2 (mild fibrosis), 3 (moderate fibrosis), 4 (severe fibrosis), and 5 (extreme 
fibrosis) [241]. 
Visceral pleural fibrosis (VPF) variable was constructed by adding 
up the scores for parenchymal bands (scale 0–5), adherences at the 
diaphragm and sinuses as well as other adherences (scales 0–3) and 
rounded atelectasis (score 0–3 for up to 2 atelectasis) considering the 
ASBE study material [242]. This sum score was then dichotomized to 
match the frequency distribution of the dichotomous VPF variable 
used in the ASSE study. Several signs of other pleural changes were also 
recorded: the extent (cm2) and greatest thickness of pleural thickenings 
(ILO “width”: 0 = no plaques, 1 ≤ 5mm, 2 = 5–10mm, 3 ≥ 10mm), and 
their degree of calcification (0 = no, 1 = sparse, 2 = a considerable part 
of the pleural thickenings, 3 = nearly all). The more detailed methods 
including the intra- and inter-reader consistencies of readings have been 
reported previously [241].
Emphysema was defined as sharply delineated low-density area(s) ac-
cording to the criteria and reference images given by Webb et al. [243]. 
The signs of centrilobular, paraseptal, panlobular, and bullae-type em-
physema were scored in both lungs by using a scale from 0 to 5: 0 (no 
changes), 1 (faint or subnormal abnormalities, in a single slice or few 
slices), 2 (slight abnormalities in some slices), 3 (clear abnormalities in 
several slices), 4 (score between 3 and 5), and 5 (abnormalities widely 
distributed in the whole lung, in all or most slices). These emphysema 
subtype scores were added up to create the emphysema sum score, its 
maximum being 20 per lung [236]. mean scores of both lungs were used 
in the analysis. The intra- and inter-reader consistencies of readings have 
been reported previously [235].
4.2.3  lung function examinations
Flow-volume spirometry was performed with a rolling-seal spirometer 
(mijnhard BV, Bunnik, Holland) connected to a microcomputer (me-
dikro mR-3; medikro, Kuopio, Finland), using Finnish reference values 
[238] and the standards of the European Respiratory Society (ERS) [244]. 
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The following parameters were measured: forced vital capacity (FVC), 
forced expiratory volume in one second (FEV1), the FEV1/FVC ratio, 
and the maximal expiratory flow where 50% of FVC remains exhaled 
(mEF50).
The single breath diffusing capacity for carbon monoxide (DLCO), 
specific diffusing capacity (diffusing capacity related to alveolar volume 
DLCO/VA), and total lung capacity (TLC) with the helium single-breath 
dilution method were measured by using a masterlab Transfer or a Com-
pact Lab Transfer device (Erich Jaeger, Würzburg, Germany) according to 
ERS recommendations [245]. Correction of DLCO was done according 
to the patient’s actual hemoglobin levels. 
The lung function variables were handled as percent of Finnish ref-
erence values [238] based on the distribution of values in the reference 
population. The FEV1/FVC ratio was considered decreased if it was < 
88% of predicted, FEV1, FVC, and TLC values if they were < 80% of 
predicted, DLCO and DLCO/VA if they were < 74% of predicted, and 
mEF50 if it was < 62% of predicted [238].
4.3  Genotyping analysis
multiplex PCR, PCR-based restriction fragment length polymorphism 
(PCR-RFLP), pyrosequencing, Taqman® allelic discrimination, and 
OpenArray®-methodology were employed in the genotyping analysis, 
depending on the type and genetic context of the SNP in question and 
methods available at the time of the analysis. Table 10 shows all the 
studied genes, polymorphic sites, and the corresponding methodology 
used in genotyping.
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Table 10. Genes, polymorphic sites, and the methods used in 
genotyping.
Gene Polymorphism Rs-number Method Reference/ID
CARD8 Ter*3Cys rs2043211 OpenArray C__11708080_1_
T/C rs1062808 OpenArray C___3218826_10
C/T rs2288877 OpenArray C__15879993_10
EPHX1 Tyr113His rs1051740 TaqMan [246]
His139Arg rs2234922 PCR-RFLP [247]
GSTM1 large deletion - Multiplex PCR [102, 248]
GSTM3 A-63C rs1332018 TaqMan [249]
---/AGG rs1799735 PCR-RFLP [250]
GSTP1 Ile105Val rs1695 PCR-RFLP [251]
GSTT1 large deletion - Multiplex PCR [102, 248]
MMP1 -/G rs1799750 Pyrosequencing -
MMP9 C-1562T rs3918242 PCR-RFLP [180]
MMP12 Asn357Ser rs652438 OpenArray C____785907_10
NLRP3 Lys705Gln rs35829419 OpenArray C__25648615_10
C/T rs10925027 OpenArray C__30713882_10
NAT2 C282T rs1041983 TaqMan [252]
T341C rs1801280 TaqMan [252]
SERPINE2 G/C rs729631 OpenArray C____803914_10
C/T rs975278 OpenArray C___7614671_10
C/G rs6748795 OpenArray C___1677432_10
C/T rs840088 TaqMan C___7614655_10
TGFβ1 Leu10Pro rs1800470 TaqMan [253]
C/T rs1800469 OpenArray C___8708473_10
G/A rs2241718 OpenArray C___7818377_1_
TIMP2 G/A rs2277698 OpenArray C__15885241_10
TNF C/T rs1799724 OpenArray C__11918223_10
G/A rs1800629 OpenArray C___7514879_10
GC Glu432Asp rs7041 OpenArray C___3133594_30
Thr436Lys rs4588 OpenArray C___8278879_10
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4.3.1  dnA extraction
DNA was extracted mechanically (Thermo King Fisher; Thermo Fisher 
Scientific, Erembodegem, Belgium) from whole blood by using BioSprint 
15 DNA Blood Kit (Qiagen GmbH, Hilden, Germany) according to 
the manufacturer´s recommendations. The extracted DNA was stored 
at -20°C until use. One hundred ng of DNA was used in PCR-reactions 
for RFLP and OpenArray® analyses, 50 ng for multiplex PCR, 30 ng for 
pyrosequencing analyses, and 20 ng for Taqman® analyses.
4.3.2  Multiplex PcR
The presence (one or two copies of the gene) or absence of GSTM1 
and GSTT1 genes was detected by using a multiplex PCR method as 
described earlier [102, 248]. Briefly, in addition to GSTM1 and GSTT1-
specific primer pairs, a primer pair specific for β-globin was added to 
the multiplex PCR-reaction. The β-globin specific fragment confirmed 
a successfully performed PCR-reaction, and the presence or absence of 
GSTM1 and/or GSTT1 specific fragments indicated the corresponding 
genotype.
4.3.3  PcR-RFlP
The 3-bp deletion of the GSTM3 gene (rs1799735) was determined 
by using restriction enzyme digestion of the PCR-product with MnlI 
[250]. The presence of the restriction site revealed the variant allele, i.e., 
the 3-bp deletion.
The GSTP1 exon 5 SNP (Ile105Val, rs1695) was analyzed by using 
PCR-RFLP method with SnaBI restriction enzyme digestion as described 
earlier [251]. The presence of the restriction site differentiated the variant 
allele from the wild type allele.
The EPHX1 exon 4 SNP (His139Arg, rs2234922) was examined by 
using PCR-RFLP method with RsaI digestion as described earlier [247]. 
The variant allele was identified through the presence of the restriction site.
The MMP9 SNP (C-1562T, rs3918242) was genotyped by using a 
PCR-RFLP-based method essentially according to [180]. Briefly, the 
concentrations of the forward (5´-TTC GTG ACG CAA AGC AGA-3´) 
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and reverse (5´-AGC AGC CTC CCT CAC TCC T-3´) primers were 
670 nm, and the cycling conditions were 95°C for 4 minutes, 34 cycles 
of 95°C for 30 seconds, 58°C for 30 seconds, and 72°C for 45 seconds 
followed by a final extension of 72°C for 5 minutes. The presence of the 
SphI restriction site revealed the variant allele.
4.3.4  Pyrosequencing
The MMP1 SNP (rs1799750) was analysed with a pyrosequencing-
method based on an assay from Pyromark Assay Database (Qiagen). 
The PCR-primers were: forward primer 5´-biotin-CCC TTA TGG 
ATT CCT GTT TTC-3´and reverse primer 5´-CCC ATT CTT CTT 
ACC CTC TTG-3´. The primer concentrations in PCR reactions were 
500 nm, and the cycling conditions were: 95°C for 5 minutes, 35 cycles 
of 95°C for 30 seconds, 54°C for 30 seconds, and 72°C for 30 seconds 
followed by a final extension of 72°C for 5 minutes.
The pyrosequencing was performed with PSQ™96mA (Qiagen) by 
using Pyromark Gold Q96 Reagents (Qiagen) according to the manu-
facturer’s recommendations. Briefly, 40 µl of the PCR product was mixed 
with 37 µl of Binding buffer and 3 µl of Streptavidin Sepharose High 
Performance beads (GE Healthcare, Uppsala, Sweden). PCR products 
bound to the beads were collected and denatured to be single-stranded 
by treatment with 70% Ethanol, Denaturation Buffer, Washing Buffer, 
and mQ water in Pyrosequencing Washing Station. The sequencing 
primer 5´-GTA GTT AAA TAA TTA GAA AG-3´ was attached to the 
template by incubating for 2 minutes in 80°C in annealing buffer. The 
pyrosequencing run was conducted in the dispensation order of CAGC-
TACTAGCA. The pyrograms were generated and analyzed with PSQ 
96 SNP Software 1.1 (Qiagen).
4.3.5  taqMan® Allelic discrimination assays
The GSTM3 promoter area SNP (rs1332018), the EPHX1 exon 3 
SNP (Tyr113His, rs1051740), two NAT2 SNPs (C282T, rs1041983; 
T341C, rs45532639), and TGFB1 SNP (rs1800470) were genotyped 
by using Taqman® allelic discrimination assays described earlier in detail 
[246, 249, 252, 253]. For the SERPINE2 rs840088 SNP, a ready-made 
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Taqman® SNP Genotyping Assay was purchased from Applied Biosys-
tems (Foster City, CA, USA) (assay ID: C__7614655_10). The assays 
were performed according to the manufacturer´s recommendations with 
Applied Biosystems 7500 Real-Time PCR system by using Taqman® 
probes. Sequence Detection Software 1.4 (Applied Biosystems) was used 
for the allele calling analysis.
4.3.6  openArray® assays
Two NLRP3 SNPs (rs35829419 and rs10925027), three CARD8 SNPs 
(rs2043211, rs1062808, and rs2288877), two TNF SNPs (rs1799724 
and rs1800629), two TGFB1 SNPs (rs1800469 and rs2241718), two GC 
SNPs (rs7041 and rs4588), one MMP12 SNP (rs652438), one TIMP2 
SNP (rs2277698), and three SERPINE2 SNPs (rs729631, rs975278, 
and rs6748795) were genotyped by using the OpenArray-system 
(BioTrove Inc., Woburn, mA), a next-generation quantitative PCR 
platform based on Taqman® chemistry. The assay IDs for Taqman® 
SNP Genotyping Assays spotted on the array were C__25648615_10, 
C__30713882_10,  C__11708080_1_,  C___3218826_10, 
C__15879993_10,  C__11918223_10,  C___7514879_10, 
C___8708473_10,  C___7818377_1_,  C___3133594_30, 
C___8278879_10,  C____785907_10,  C__15885241_10, 
C__803914_10, C__7614671_10, and C__1677432_10, respectively. 
The plate format of 16 SNPs and 144 samples per array were used. 
The allele calling analysis was performed using OpenArrayTm SNP 
Genotyping Analysis software (BioTrove Inc.).
4.3.7  Quality control
For the quality control, two independent readers interpreted the results 
and a random selection of 10% of all samples was re-tested. minor error 
rates were detected for the OpenArray assays rs1799724 (1%), rs2043211 
(1%), rs975278 (1%), rs6748795 (1%), rs1800629 (2%), rs2241718 
(2%), rs2277698 (2%), and rs1800469 (3%).
In order to verify the reliability of OpenArray platform, a random 
selection of 15% of samples was re-analyzed for TNF rs1800629 and 
rs1799724 SNPs with 100% concordant results with the earlier esti-
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mates. The re-analyses were conducted with a PCR-RFLP method [254] 
(rs1800629) and a pyrosequencing-based method (rs1799724), designed 
by using Pyromark Assay Design 1.0 -tool (Qiagen). 
The primers and probes for the pyrosequencing protocol were as follows: 
forward primer: 5´-GGT AGG AGA ATG TCC AGG GCT ATG-3´, bio-
tinylated reverse primer: 5´-biotin-ACT CCC TGG GGC CCT CTA-3´, 
and sequencing primer: 5´-TCG AGT ATG GGG ACC-3´. The primer 
concentrations in PCR reactions were 200 nm, and the cycling conditions 
were: 95°C for 5 minutes, 39 cycles of 95°C for 15 seconds, 56°C for 30 
seconds, and 72°C for 15 seconds followed by a final extension of 72°C 
for 5 minutes. The pyrosequencing was performed with PSQTm96mA 
(Qiagen) by using Pyromark Gold Q96 Reagents (Qiagen) as described 
above for the analysis of the MMP1 rs1799750 SNP.
4.4  statistical and bioinformatics methods
4.4.1  Power calculations
The studies had variable powers to detect associations, depending on 
the minor allele frequency (mAF) and study size: Study I (n = 1008) 
had 80% power to detect odds ratios (ORs) from 1.54 to 1.80 (mAF 
13–46%), Study II (n = 988) had 80% power to detect ORs from 1.45 
to 1.66 (mAF 13–46%), Study III (n = 951) had 80% power to detect 
ORs from 1.66 to 1.72 (mAF 21–28%), Study IV (n = 951) had 80% 
power to detect ORs from 1.46 to 2.30 (mAF 4–42%), and Study V (n 
= 951) had 80% power to detect ORs from 1.57 to 2.63 (mAF 4–42%). 
The calculations, based on a two-sided alpha of 0.05, were performed 
by using standard methods.
4.4.2  Association analysis
The associations between genotypes/haplotypes, radiologic parameters, 
and lung function parameters (FEV1, FVC, FEV1/FVC, mEF50, DLCO, 
DLCO/VA, and TLC) were evaluated by using linear regression analysis. 
Logistic regression analysis was used to evaluate the potential confound-
ers and to further study the risk for pleuropulmonary changes and their 
severity with certain genotype/haplotype.
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Covariates considered in the analyses included sex, age, pack years of 
smoking (PYs), years of asbestos exposure, height, and FEV1: the covari-
ate pattern was selected depending on the particular research question. 
In papers I–III, occasionally lacking covariate data was replaced by the 
group mean value (47 replacements for asbestos exposure, 20 replace-
ments for smoking exposure, and 68 replacements for height)
The χ2 analysis was used to test the deviation of the genotype distri-
butions from the Hardy-Weinberg equilibrium (HWE).
All of the data analyses were performed by using the SPSS version 
18.0 (SPSS Inc., Chicago, IL).
4.4.3  Population stratifications
For further analysis, the cases were divided according to the existence of 
the radiologic changes. In Studies I and V, the radiologic signs of fibrosis 
were considered mild/subnormal if the radiological score was < 2, and 
severe/pathological if the score was ≥ 2. In addition, the greatest thickness 
of pleural plaques was categorized as < 5 or ≥ 5 mm and their extent as ≤ 
100 or > 100 cm2. For Studies II–IV, the radiologic signs of emphysema 
were considered either mild/subnormal if the radiologic score was < 1 
(< 2 in emphysema sum score), or severe/pathological if the radiologic 
score was ≥ 1 (≥ 2 in emphysema sum score). For the stratified analyses 
on smoking habits in study III, the subjects who had smoked less than 
25 PYs were categorized as mild smokers, and subjects who had smoked 
for at least 25 PYs were considered as moderate/heavy smokers.
4.4.4  Phenotype construction
The two polymorphic loci of NAT2 are considered to provide sufficient 
information for reliable prediction of the NAT2 phenotype in Caucasian 
populations [255]. Consequently, the subjects were categorized into fast 
and slow NAT2-acetylators according to the presence of wild-type and 
variant alleles in these two loci; subjects with two variant alleles were 
considered as slow acetylators, all others were included in the fast acety-
lator category [256]. Similarly, the EPHX1 diplotypes were categorized 
in the putative phenotype groups (high, intermediate, and low activity) 
essentially according to [257].
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4.4.5  linkage disequilibrium and haplotype 
construction
For papers III–V, the linkage disequilibrium (LD) structure was examined 
by using HaploView program, version 4.2 [258]. When moderate or 
strong linkage (r2 > 0.5) was detected, haplotypes consisting of the SNPs 
in question were statistically reconstructed from population genotype 
data with the markov chain method for haplotype assignments by using 
the PHASE program (version 2.1) [259]. The associations of the haplo-
types to pulmonary parameters were examined as with the single SNPs.
4.4.6  database search
For papers IV and V, the F-SNP program [260], connected to main 
databases, was used to predict the function of the intronic SNPs studied, 
and the SNP Annotation and proxy search (SNAP) [261] was used to 
examine the LD of the studied SNPs in the 1000 Genomes Population 
(1KGP).
To further clarify the potential role of SERPINE2 and its polymor-
phisms in the development of lung tissue destruction, the mADCOW-
tool [262] was used to perform a microarray database search in order 
to locate genes that are co-expressed with SERPINE2. The genes in the 
resulting list were then classified by using the DAVID 6.7 functional 
annotation tool [263]. 
The eQTL Browser [264] was used to identify polymorphisms poten-
tially associated to the expression of the studied genes from a microarray 
database.
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5.1  conformity of the genotype distribution 
 with hWe in the study population
The genotype and putative phenotype frequencies of the studied poly-
morphisms in GSTM1, GSTM3, GSTP1, GSTT1, EPHX1, and NAT2 
genes were similar in the construction workers and the demographic 
references (Supplemental Table 1 in Papers I and II). In addition, these 
polymorphisms were in HWE among the demographic references (p 
> 0.05). The rest of the polymorphisms in CARD8, MMP1, MMP9, 
MMP12, NLRP3, SERPINE2, TGFB1, TIMP2, TNF and GC genes 
were studied only among the construction workers; almost all of them 
were in HWE (p > 0.09), except the CARD8 rs1062808 and rs2288877 
SNPs (p < 0.01). These SNPs were omitted from further analysis.
5.2  linkage disequilibrium structures
Three of the studied SERPINE2 SNPs (rs729631, rs975278, and 
rs6748795) were found to be in tight linkage disequilibrium (r2 ≥ 
0.980). The haplotype block structure and pair-wise LD (D´) values for 
the studied SERPINE2 SNPs are shown in Figure 8. Since examining 
several SNPs in almost complete linkage is not expected to offer any 
additional information, only one of these SNPs (rs729631) was cho-
sen to be examined further in addition to the fourth SERPINE2 SNP 
(rs840088), which was in moderate linkage with the other three SNPs 
(D´ = 0.500–0.551, r2 = 0.027–0.031).
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Figure 8. Linkage disequilibrium (LD) between the studied SERPINE2 SNPs in 
the construction workers. Values of D´ are shown.
In addition, a moderate LD was observed between GC rs4588 and rs7041 
SNPs (r2 = 0.501) and TGFB1 rs1800469 and rs1800470 SNPs (r2 = 
0.738). The haplotype block structure and D´ values for the GC and 
TGFB1 SNPs are shown in Figure 9.
For NLRP3 rs35829419 and TNF rs1799724 SNPs, the minor allele 
frequencies were too small (0.3 % and 0.2 %, respectively) for r2 to detect 
LD, despite the maximum D´s (D´ = 1.00, r2 = 0.032 for rs35829419; 
D´ = 1.00, r2 = 0.008 for rs1799724).
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Figure 9. Linkage disequilibrium (LD) between the studied TGFB1 SNPs (A) 
and GC SNPs (B) among the construction workers. Values of D´ are shown.
5.3  Reconstructed haplotypes
The haplotype analysis identified four different haplotypes for SERPINE2 
rs729631 and rs840088 SNPs. The most common of these was the GC 
(wild type-wild type, 55.0%) followed by GT (24.4%), CC (16.9%), 
and CT (3.7%). For GC rs4588 and rs7041 SNPs, three haplotypes were 
identified: the most common was GC (wild type-wild type, 65.2%), 
followed by TA (21.1%), and GA (13.7%). For TGFB1 rs1800469 and 
rs1800470 SNPs, four haplotypes were identified: GT (wild type-wild 
type, 60.5%), GC (24.9%), AT (10.3%), and AC (4.3%).
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5.4  Genetic predisposition to fibrotic    
 changes
Several significant associations were found between the studied poly-
morphisms and fibrotic pleuropulmonary changes in the construction 
workers (Table 11). The GSTT1 deletion polymorphism and the NLRP3 
rs35829419 SNP were found to be associated with interstitial lung fibro-
sis (p = 0.003 and p = 0.013, respectively), and the TGFB1 rs2241718 
SNP with visceral pleural fibrosis (p = 0.044). In addition, the GSTM1 
deletion polymorphism and the CARD8 rs2043211 SNP were found to 
be associated with the greatest thickness of pleural plaques (p = 0.009 
and p = 0.015, respectively) and the TIMP2 rs2277698 SNP with the 
calcification of pleural plaques (p = 0.037) (Table 11). No associations 
were found between the studied polymorphisms and the extent of the 
area covered by pleural plaques.
Table 11. Significant associations between gene polymorphisms and 
fibrotic pleuropulmonary changes.
Phenotype Gene Polymorphism β1 p-value Reference
Interstitial lung 
fibrosis
GSTT1 deletion -0.09 0.003 Paper I
NLRP3 rs35829419 0.078 0.013 Paper V
Visceral pleural 
fibrosis
TGFB1 rs2241718 -0.66 0.044 Paper V
Pleural plaques
Greatest thickness GSTM1 deletion -0.008 0.009 Paper I
CARD8 rs2043211 0.076 0.015 Paper V
Calcification TIMP2 rs2277698 0.063 0.037 Paper V
1 Standardized coefficient
In the stratified analysis, the GSTT1 null genotype was found to pose 
a three-fold risk for pathological fibrotic changes (OR 3.12, 95% CI 
1.51–6.43) compared to the wild type genotype. Similarly, the carriage 
of at least one NLRP3 rs35829419 variant A-allele was found to pose an 
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almost 2.5–fold risk for developing pathological fibrotic changes (OR 
2.44, 95% CI 0.97–6.14) although this association was only borderline 
statistically significant (Table 12). In contrast, the carriage of at least one 
TGFB1 rs2241718 variant allele was found to reduce the risk for visceral 
pleural fibrosis (OR 0.62, 95% CI 0.39–0.98) (Table 13).
The GSTM1 null genotype was found to slightly elevate the risk for 
≥ 5-mm thick pleural plaques (OR 1.36, 95% CI 1.03–1.80) compared 
to the wild type genotype (Table 14), and the carriage of at least one 
TIMP2 rs2277698 variant A-allele posed an almost two-fold risk for 
a high calcification degree in the pleural plaques (OR 1.90, 95% CI 
1.09–3.33) (Table 15).
When the haplotypes were studied, the TGFB1 rs1800469–
rs1800470 haplotype was found to be associated with the calcification 
degree of pleural plaques (p = 0.035) (data not shown). In stratified 
analysis, the GC and AT haplotypes were found to increase the risk for 
calcification of the pleural plaques with ORs of 1.52 (95% CI 1.09–2.11) 
and 1.95 (95% CI 1.18–3.22), respectively, compared to the most com-
mon haplotype GT. The risks did not notably differ between the mild 
and high degree of calcification (Table 16).
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Table 13. Distribution of TGFB1 rs2277698 genotypes 
according to the existence of visceral pleural fibrosis. 
Genotype No changes1 Any changes OR (95% CI)
TGFB1
G/G 577 (72.5) 104 (80.6) 1.0
G/A or A/A 219 (27.5) 25 (19.4) 0.62 (0.39–0.98)
Data are presented as n (%), unless otherwise stated
1 Reference category
Table 14. Distribution of GSTM1 genotypes according to 
the thickness of pleural plaques.
Genotype Greatest thickness
< 5 mm1 ≥ 5 mm OR (95% CI)
GSTM1
null 181 (58.2) 353 (50.8) 1.0
present 130 (41.8) 342 (49.2) 1.36 (1.03–1.80)
Data are presented as n (%), unless otherwise stated
1 Reference category
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5.5  Genetic predisposition to pulmonary   
 emphysema
The significant associations between studied polymorphisms and emphy-
sematous changes are shown in Table 17. Among construction workers, 
the GSTT1 deletion polymorphism and EPHX1 rs1051740 SNP were 
found to be associated with overall (p = 0.008 and p = 0.007, respec-
tively), paraseptal (p = 0.015 and p = 0.039), panlobular (p = 0.031 and 
p = 0.013), and bullae-type emphysematous changes (p = 0.045 and p 
= 0.003). In addition, TIMP2 rs2277698 SNP was found to be associ-
ated with overall (p = 0.022) and paraseptal emphysema (p = 0.010), 
MMP9 rs3918242 SNP to centrilobular emphysema (p = 0.008), TNF 
rs1800629 SNP to paraseptal emphysema (p = 0.017), and SERPINE2 
rs729631 SNP to panlobular emphysema (p = 0.003) (Table 17).
Table 17. Significant associations between gene polymorphisms and 
emphysematous changes.
Phenotype Gene Polymorphism 1 p-value Reference
Emphysema, all GSTT1 deletion -0.080 0.008 Paper II
EPHX1 rs1051740 -0.082 0.007 Paper II
TIMP2 rs2277698 0.071 0.022 Paper IV
Centrilobular TGFB1 rs2241718 -0.071 0.022 Paper IV
MMP9 rs3918242 -0.082 0.008 Paper IV
Paraseptal GSTT1 deletion -0.075 0.015 Paper II
EPHX1 rs1051740 -0.064 0.039 Paper II
TNF rs1800629 0.075 0.017 Paper IV
TIMP2 rs2277698 0.081 0.010 Paper IV
Panlobular GSTT1 deletion -0.067 0.031 Paper II
EPHX1 rs1051740 -0.077 0.013 Paper II
SERPINE2 rs729631 0.094 0.003 Paper III
Bullae GSTT1 deletion -0.063 0.045 Paper II
EPHX1 rs1051740 -0.093 0.003 Paper II
1 Standardized coefficient
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The associations between EPHX1 rs1051740 SNP and emphysema 
did not appear in the stratified analysis. Instead, the GSTT1 null geno-
type was found to pose a two-fold overall risk for emphysema (OR 2.01, 
95% CI 1.33–3.03). When the emphysema subtypes were examined 
separately, the ORs were 2.05 for centrilobular (95% CI 1.31–3.20), 
2.52 for paraseptal (95% CI 1.60–3.97), 1.73 for panlobular (95% CI 
1.10–2.74), and 2.43 for bullae-type changes (95% CI 1.51–3.91). 
Furthermore, the carriers of the GSTT1 null genotype had an almost 
four-fold risk (OR 3.70, 95% CI 2.15–6.36) for developing pathological 
changes compared to the subjects who possessed the gene. The risks for 
subnormal or pathological changes did not greatly differ from the risk 
of overall changes in the different emphysema subgroups (Table 18).
Similarly to EPHX1 rs1051740 SNP, no association between TIMP2 
rs2277698 SNP and overall emphysema emerged in the stratified analysis. 
Instead, the carriage of at least one TIMP2 rs2277698 variant A-allele 
was found to pose a two-fold risk for pathological paraseptal emphy-
sema (OR 1.94, 95% CI 1.14–3.30). In addition, the carriage of at 
least one TNF rs1800629 variant A-allele was found to pose a two-fold 
risk for overall (OR 2.03, 95% CI 1.38–2.98), subnormal (OR 2.12, 
95% CI 1.30–3.48), and pathological (OR 2.10, 95% CI 1.24–3.56) 
paraseptal emphysema. In contrast, the carriage of at least one TGFB1 
rs2241712 variant A-allele was found to halve the risk for pathological 
centrilobular emphysema (OR 0.53, 95% CI 0.30–0.90), as did the car-
riage of at least one MMP9 rs3918242 variant T-allele (OR 0.51, 95% 
CI 0.30–0.86) (Table 18). In combination, the variant allele genotypes 
of TGFB1 rs2241718 and MMP9 rs3918242 loci were found to reduce 
the risk of centrilobular emphysema to one fifth compared to the wild 
type genotypes (OR 0.22, CI 95% 0.08–0.61) (Table 19). No other 
gene-gene interactions were observed.
The homozygous variant of SERPINE2 rs729631 SNP was found 
to pose an over two-fold risk for developing panlobular emphysema 
(OR 2.22, 95% CI 1.05–4.72). The risk was slightly increased also for 
the heterozygotes (OR 1.66, 95% CI 1.15–2.38), and it appeared to 
be mainly attributable to the pathological emphysematous changes; the 
risk was over two-fold for heterozygotes (OR 2.19, 95% CI 1.23–3.91) 
and over four-fold for homozygotes (OR 4.37, 95% CI 1.61–11.86) as 
compared to subjects with the wild type genotype (Table 18).
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In the haplotype analysis, the SERPINE2 rs729631–rs840088 haplo-
type was found to be associated with panlobular emphysema (p = 0.014) 
(data not shown). In stratified analysis, the CC-haplotype (variant allele 
for rs729631, wild type allele for rs840088) showed almost a 1.5-fold 
risk for overall panlobular emphysema (OR 1.41, 95% CI 1.04–1.92) 
and an over two-fold risk for pathological panlobular changes (OR 2.23, 
95% CI 1.41–3.54) in comparison to the most common haplotype with 
the wild type allele in both SNPs (GC). The haplotype with a variant 
allele for both SNPs (CT) showed an almost four-fold risk for overall 
panlobular changes (OR 3.72, 95% CI 1.56–8.90), and subnormal 
panlobular changes (OR 3.98, 95% CI 1.55–10.20) in comparison to 
the most common haplotype (GC) (Table 20).
In addition, the TGFB1 haplotype (rs1800469–rs1800470) was 
found to be associated with centrilobular emphysema (p = 0.018) (data 
not shown). In the stratified analysis, the AT-haplotype was found to 
almost halve the risk for pathological centrilobular emphysema (OR 
0.55, 95% CI 0.33–0.93) in comparison to the most common haplotype 
(GT) (Table 21).
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5.6  Genetic association to lung function
Significant associations between studied polymorphisms and lung func-
tion among all construction workers are shown in Table 22. The CARD8 
rs2043211 SNP was found to be associated with FEV1, FVC, and mEF50 
(p = 0.022, p = 0.047, and p = 0.032, respectively). The GSTT1 deletion 
polymorphism was associated with DLCO and DLCO/VA (p = 0.021 and p 
= 0.002, respectively) as was the NAT2 rs1041983 SNP (p = 0.007 and 
p = 0.006, respectively). The GSTM3 rs1332018 SNP was associated 
with FEV1/FVC and mEF50 (p = 0.010 and p = 0.032, respectively), 
and EPHX1 rs1051740 and TIMP2 rs2277698 SNPs with mEF50 (p 
= 0.008 and p = 0.013, respectively) (Table 22). No associations were 
found between the studied polymorphisms and TLC.
Table 22. Significant associations between gene polymorphisms and 
lung function.
Phenotype Gene Polymorphism 1 p-value Reference
FEV1 CARD8 rs2043211 0.073 0.022 Unpublished
2
FVC CARD8 rs2043211 0.065 0.047 Unpublished2
FEV1/FVC GSTM3 rs1332018 -0.077 0.010 Paper II
TIMP2 rs2277698 -0.066 0.035 Paper IV
DLCO GSTT1 deletion 0.062 0.021 Paper I
NAT2 rs1041983 -0.075 0.007 Paper I
DLCO/VA GSTT1 deletion 0.095 0.002 Paper I
NAT2 rs1041983 -0.086 0.006 Paper I
MEF50 TIMP2 rs2277698 -0.084 0.008 Paper IV
GSTM3 rs1332018 -0.067 0.032 Unpublished2
EPHX1 rs1051740 0.078 0.013 Unpublished2
CARD8 rs2043211 0.067 0.032 Unpublished2
1 Standardized coefficient
2 Adjusted with pack-years and years of asbestos exposure
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The associations between CARD8 rs2043211 SNP and FEV1, FVC, 
and mEF50 did not emerge in the stratified analysis. Instead, the 
GSTT1 null genotype was found to pose a 1.8-fold risk (OR 1.77, 95% 
CI 1.06–2.95, p = 0.029) for decreased DLCO and 2.4-fold risk (OR 
2.37, 95% CI 1.33–4.23, p = 0.003) for decreased DLCO/VA (Table 
23); the average values were 87.2±21.5 (DLCO) and 93.2±20.7 (DLCO/
VA) among subjects with GSTT1 null genotype, and 91.6±20.0 and 
99.0±18.0 among subjects with the wild type genotype (p = 0.030 and 
p = 0.002, respectively) (unpublished data). When only subjects with 
fibrotic changes were considered, the risk for decreased pulmonary dif-
fusing capacity was a somewhat higher; the ORs were 1.88 (95% CI 
1.10–3.21) for DLCO and 2.81 (95% CI 1.55–5.12) for DLCO/VA (Paper 
I). In addition, the DLCO and DLCO/VA values were significantly lower (p 
= 0.004 and p = 0.003, respectively) among subjects homozygous with 
NAT2 rs1041983 variant T-allele (83.8±18.2 and 92.6±17.1) compared 
to subjects with the wild type genotype (92.6±20.6 and 99.9±18.0, 
respectively) (unpublished data).
Table 23. Distribution of GSTT1 genotypes according to pulmonary 
diffusing capacity.
GSTT1 
genotype
DLCO
< 74% pred ≥ 74% pred OR (95% CI)
null 145 (81.9) 686 (87.8) 1.0
present 32 (18.1) 95 (12.2) 1.77 (1.06–2.95)
DLCO/VA
< 74% pred ≥ 74% pred OR (95% CI)
null 72 (77.4) 761 (87.8) 1.0
present 21 (22.6) 106 (12.2) 2.37 (1.33–4.23)
Data are presented as n (%), unless otherwise stated
No associations between EPHX1 rs1051740 SNP and mEF50 were 
detected in the stratified analysis. Instead, subjects with at least one 
TIMP2 rs2277698 variant A-allele had a significantly (p = 0.011) lower 
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mEF50 (61.0 ±27.0) than subjects with the wild type G/G genotype 
(67.0±29.9). Similarly, the FEV1/FVC-ratio tended to be lower (p = 
0.136) in those subjects who were homozygous for the TIMP2 rs2277698 
variant A-allele (89.1±9.3) when they were compared to subjects with the 
wild type G/G genotype (93.8±12.7) (Paper IV). In addition, subjects 
homozygous for the GSTM3 rs1332018 variant C-allele had significantly 
(p = 0.049) lower mEF50 (62.0±26.7) and somewhat (p = 0.107) lower 
FEV1/FVC-ratio (92.2±11.8) than subjects with wild type A/A genotype 
(68.6±30.8 and 94.8±12.5, respectively) (unpublished data).
In Paper III, lung function was analysed also among subjects with 
panlobular emphysema. The FEV1 appeared to decrease in parallel to 
the number of the variant C alleles in SERPINE2 rs729631 locus (GG 
77.8±22.5, GC 73.7±23.0 and CC 70.2±19.0). The same trend was seen 
for FVC, which was significantly (p = 0.023) lower with homozygous CC 
variants in comparison to the carriers of GG genotype (GG 94.1.8±17.2, 
GC 87.5±20.1, CC 81.3±16.6).
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Tobacco smoking is a major global health burden being responsible for 
several millions of deaths yearly all over the world. It has been shown to 
increase the risk for different malignancies, and to promote the develop-
ment of cardiovascular and respiratory disorders [3]. 
Since there are currently national bans and restrictions in place, the 
widespread use of asbestos has passed into history. However, the pre-
vious exposures still represent a significant health concern due to the 
huge amounts of asbestos mined and used in different insulation and 
construction purposes since the early 1900s and the long latency period 
of most asbestos associated diseases [2].
Both tobacco smoke and asbestos fibers enter the body mainly by 
inhalation, which makes the respiratory tract especially vulnerable to 
their toxic effects. In the lungs, foreign compounds may induce oxidative 
stress, alter the protease-antiprotease balance, induce innate and adaptive 
immune responses, and create the conditions of persistent inflammation 
leading eventually to lung injury. However, the type and severity of lung 
injury vary greatly between individuals, even with similar exposure histo-
ries. These differences are believed to originate from the complex interplay 
between genetic, epigenetic, environmental, and life course factors [13].
6.1 state of the association studies    
 investigating asbestos and smoking   
 related non-malignant lung diseases
The genetic background of COPD has been extensively studied with 
hundreds of publications including also large meta-analysis and GWA-
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studies. These investigations have identified more than a hundred genes 
with positive associations to COPD, COPD related traits, and lung 
function [265], probably due to the high prevalence of the disorder 
and relatively simple diagnostic procedures. The genetics of pulmonary 
emphysema has also attracted considerable interest, not least because of 
the influence of the hereditary AAT-deficiency. Nonetheless, the high 
cost and inconvenience of the imaging methods have limited the avail-
ability of the study material, and only a handful of association studies 
have been published examining CT-assessed emphysema, emphysema 
severity, or different emphysema subtypes. 
The factors that determine individual susceptibility to asbestos as-
sociated non-malignant lung diseases have been rather poorly studied. 
There are, however, a few association studies on asbestosis; these have 
mainly concentrated on the genes participating in the metabolism of 
xenobiotics and products of oxidative stress.
6.2  Xenobiotic metabolizing enzyme genes
6.2.1  GSTM1
The gene deletion of the most widely studied member of the GST family, 
GSTM1, has been associated with an increased risk of several malignant 
and non-malignant conditions, including COPD [118, 119]. Although 
several reports have failed to confirm this finding [140, 145, 266, 267], 
the results from recent meta-analyses have indicated that the GSTM1 null 
genotype could pose a slightly elevated risk for COPD in both Asian and 
Caucasian populations [106, 108, 109]. The lack of GSTM1 gene has 
also been proposed to increase the risk for pulmonary emphysema [120]. 
In the current study, no significant associations were found between 
the GSTM1 polymorphism and neither emphysema nor a lung function 
decline. This is in contrast to a previous report linking GSTM1 genotype 
to the development of emphysema [120]. However, that finding was 
based on a very small sample size (43 smoking cases and 179 controls 
without known smoking status), and it is unclear whether any potential 
confounders were taken into account in the statistical analysis. moreover, 
two subsequent studies have failed to associate the GSTM1 genotypes 
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to CT-defined emphysema and emphysema distribution [141, 142]. It 
therefore seems that even though GSTM1 deficiency may increase the 
risk of COPD, this is not attributable to the emphysema component 
of the disease.
The present study did not reveal any significant associations between 
the GSTM1 deletion polymorphism and asbestos induced fibrotic 
changes or pleural plaques. This contrasts both the previous finding from 
our research group that the GSTM1 deficiency in combination with 
NAT2 slow acetylator genotype increases the risk for asbestos associated 
non-malignant lung diseases [102], and the observation that the GSTM1 
deletion alone elevates the risk for asbestos related parenchymal changes 
[101]. The findings of the current study are, however, in agreement with 
three other reports which also failed to detect any associations between 
GSTM1 and asbestos-related abnormalities [100, 104, 105]. 
The discrepancy between the different studies may partly be due to 
the different inclusion criteria for cases; in some of the previous studies 
all non-malignant disorders were grouped together [102, 105] while 
in the current study, fibrotic changes and pleural plaques were studied 
separately. The duration and intensity of the asbestos exposure, which 
are very hard to assess, have also been inconsistently reported in the 
published reports. In addition, most of the previous studies were rather 
small, with less than 100 cases included [100–102, 104]. 
6.2.2  GSTT1
Similarly to the GSTM1 polymorphism, the GSTT1 deletion poly-
morphism has been widely studied in relation to lung diseases, and a 
deficiency of the gene has been associated to increased risk of COPD 
and lung function decline [121, 266–269]. The recent meta-analyses, 
however, have indicated that the GSTT1 deficiency does not signifi-
cantly affect the risk of COPD [106, 108, 109, 113], and it has also 
been failed to be associated to emphysema [141]. On the other hand, 
GSTT1 deficiency has been postulated to protect against the develop-
ment of asbestosis [105].
In the current study, significant associations were found between the 
GSTT1 genotype and pulmonary emphysema, interstitial lung fibrosis, 
and diffusing capacity for carbon monoxide (DLCO and DLCO/VA); these 
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associations were significant in both of the study cohorts. In the stratified 
analysis, deletion of the GSTT1 gene was found to increase the risk for 
severe fibrotic changes, severe emphysematous changes of any type, and 
decreased gas transfer capacity.
Although the present findings do not agree with the results from 
previous studies, they are consistent with the functional consequences 
of the associated polymorphism; deletion of an XmE gene would be 
anticipated to lead to a reduced detoxification capacity and the accumula-
tion of oxidative agents, which, in turn, could evoke a lung tissue injury 
and promote the development of pulmonary disorders and functional 
impairment.
The main difference between the present and previous studies is the 
sample size; our study population comprised of over one thousand con-
struction workers, 351 of whom had emphysematous changes of different 
types and 750 of whom exhibited various degrees of interstitial fibrosis. 
In earlier studies the amount of emphysema and fibrosis patients has been 
much smaller, varying from a few tens to a couple of hundred [100–105, 
120]. Consequently, the elevated risk which was detected only for severe 
changes in the present study could well have gone unrecognized in the 
previous studies with much smaller sample sizes, where stratification 
was not appropriate.
Since a reduced diffusing capacity is a characteristic of both emphy-
sema and asbestosis, the associations found in the present study clearly 
support each other suggesting that the absence of GSTT1 activity might 
lead to an increase in many kinds of structural changes in the lungs, 
simultaneously or separately, depending probably on the type and dura-
tion of the exposures and their interaction with other inherited factors. 
The exact mechanism of this process and the genes involved, however, 
remain to be clarified.
6.2.3 GSTP1
The GSTP1 gene has also been fairly extensively studied in relation to 
lung diseases; the functional Ile105Val polymorphism in GSTP1 has 
previously been associated with COPD, emphysema distribution, asbes-
tosis, and impairment of lung function [104, 121, 127, 128, 142, 268, 
269]. Results from recent meta-analyses are, however, rather inconsistent; 
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in one study, the Val-allele was found to be a risk factor for COPD in 
Caucasians but protective among Asian populations [108]. A subsequent 
study supported the disadvantageous effect of Val-allele among Cauca-
sians, but disputed its protective influence among Asians [111], and in 
a third study the Val-allele was found to be protective among a mixed 
Caucasian/Asian population [110]. moreover, yet another meta-analysis 
failed to detect any effects for GSTP1 Ile105Val polymorphism on the 
development of COPD [109]. 
In the current study, no significant associations were found between 
GSTP1 Ile105Val polymorphism and non-malignant pulmonary or 
pleural changes. This contrasts with the results of some of the earlier 
studies, most of which were carried out in smaller research frames than 
the current study. For instance, only 61 asbestos exposed persons were 
included in one of these studies [104]. In addition, the contradictory 
results from meta-analyses indicate that the relationship between GSTP1 
Ile105Val polymorphism and COPD is far from being straightforward; 
although racial differences may partly explain the discrepancies, there 
most probably are other, yet unidentified genetic and/or epigenetic fac-
tors contributing to the pathogenesis of COPD along with GSTP1. It 
is clear that better characterized study populations would be valuable if 
one wishes to reveal the exact phenotypes or COPD related traits that 
could be attributed to changes in the function of GSTP1.
6.2.4  GSTM3
The GSTM3 gene has been much less studied in terms of pulmonary 
disorders than the other GST genes, and its polymorphisms have not 
been associated to COPD or asbestos related lung diseases. However, 
in the current study, a significant association was found between the 
GSTM3 promoter polymorphism (rs1332018), FEV1/FVC-ratio, and 
mEF50; the mEF50 was significantly reduced and FEV1/FVC-ratio 
somewhat, but not statistically significantly, reduced among individu-
als with homozygous rs1332018 variant allele genotype. Both reduced 
mEF50 and FEV1/FVC-ratio indicate peripheral obstruction typical of 
smoking associated COPD and emphysema [270].
Interestingly, one previous report has indicated a role for GSTM3 ex-
pression in emphysema severity; the gene was found to be over-expressed 
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in the lungs of former heavy-smokers with a low FEV1/FVC-ratio [123]. 
In another large cohort of children, a certain GSTM3 haplotype and a 
three base-pair deletion (rs1799735) were found to be associated with a 
decrease in the growth for maximum midexpiratory flow rate (mmEF) 
[271]. In the same cohort, the deletion polymorphism rs1799735 
was found to exist in tight linkage with the promoter polymorphism 
rs1332018, which was associated with altered mEF50 in the current 
study. 
The rs1332018 SNP has been postulated to affect the GSTM3 expres-
sion [122], and by using the eQTL Browser [264], we found a microarray 
study supporting this view [272]. Hence, based on the results from the 
current and previous works, it seems plausible that the variant genotype 
of GSTM3 promoter polymorphism, associated with decreased mEF50 
and FEV1/FVC-ratio in the present study, increases the expression of the 
gene in the lungs, leading to increased metabolism of certain tobacco 
smoke components. In this way it could contribute to the development 
of pulmonary obstruction and possibly to emphysema.
6.2.5  EPHX1
The two functional EPHX1 polymorphisms, Tyr113His (rs1051740) and 
His139Arg (rs2234922), predicting slow or fast EPHX1 activity, have 
been widely studied in relation to malignant and non-malignant lung 
diseases [273–275]. The slow activity related His-alleles and a putative 
slow EPHX1 activity phenotype have previously been associated to the 
development of COPD, emphysema, and impairment of lung function 
[118, 128, 137–143]. Other EPHX1 polymorphisms have also been 
connected to several COPD-related traits including emphysema distri-
bution and airway wall phenotype [129, 142, 144]. However, there are 
several reports which have not found any association between EPHX1 
genotypes and COPD, emphysema and/or lung function [145, 146, 
148, 150, 151]. In addition, the results from previous meta-analyses 
are rather conflicting; two studies [108, 109] could not confirm the 
associations between EPHX1 polymorphisms and COPD, while two 
other studies [107, 112] suggested that the risk for COPD might be 
marginally increased by the His-alleles. 
93
6 discussion
In the current study, significant associations were observed between 
EPHX1 rs1051740 SNP (Tyr113His), mEF50, and emphysema. This 
is essentially in agreement with previous positive association studies 
concerning emphysema [129, 141, 142]. However, in the stratified 
analysis none of the initial associations emerged and therefore the role 
of EPHX1 Tyr113His polymorphism in the development of pulmonary 
emphysema and obstruction remains tentative until replicated in an 
independent study cohort.
The EPHX1 slow activity phenotype has also been associated with 
the development of pleural plaques among asbestos associated workers 
[104]. Since almost all of our study subjects had pleural plaques, we were 
only able to examine the extent, greatest thickness, and calcification of 
pleural plaques instead of their existence. However, none of these meas-
ures were found to be associated with EPHX1 genotypes or phenotypes. 
6.2.6  NAT2
Although genetic variation of NAT2 has been extensively studied in relation 
to lung cancer [276], much less data exists on NAT2 polymorphisms and 
chronic pulmonary disorders. Our research group has previously found an 
association between the NAT2 slow acetylator genotype and non-malignant 
pulmonary disorders among asbestos exposed workers; the risk of having 
non-malignant changes was over four-fold for patients with a combina-
tion of NAT2 slow acetylator genotype and GSTM1 null genotype [102]. 
Unfortunately, it was not possible to confirm the previous findings in 
the current study. As discussed in the context of GSTM1, this discrepancy 
could be due to the different inclusion criteria for cases; in the previous 
study all non-malignant disorders were grouped together, while in the 
current study fibrotic changes and pleural plaques were studied separately. 
In addition, the incoherence between the previous and current findings 
could be partly explained by differences in the exposure level and/or the 
asbestos type to which the subjects were exposed; in the earlier report, 
the workers were all heavily exposed to asbestos, and the exposure was 
confirmed with a lung fiber burden measurement, whereas in the cur-
rent study, the workers were exposed to various levels of asbestos and no 
fiber measurements were performed. The sample size was also remarkably 
smaller in the earlier study.
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The slow NAT2 acetylator genotype has also been previously associ-
ated with the development of COPD [133]. In the current study, DLCO 
and DLCO/VA values were found to be significantly lower among subjects 
homozygous with NAT2 rs1041983 variant allele compared to subjects 
with the wild type genotype. Although the rs1041983 SNP defines the 
NAT2 acetylator phenotype together with rs45532639, it was not pos-
sible to detect any associations between the acetylator phenotype and 
emphysema or lung function. Hence, there is inadequate evidence to 
support the involvement of NAT2 in the development of asbestos and 
tobacco smoke related non-malignant pulmonary disorders until this 
association can be confirmed in an independent study population. 
6.3  Genes involved in  
 protease-antiprotease balance
6.3.1  SERPINE2
SERPINE2 was identified as a COPD candidate gene in 2006 by gene 
expression analysis [156]. Subsequently, several SERPINE2 SNPs have 
been associated with COPD in two large family and case-control -based 
Caucasian populations [156, 162] and in two Asian populations [163, 
164]. There are, however, one Caucasian [165] and two Asian [166, 167] 
studies that have failed to replicate these findings. Interestingly, certain 
SERPINE2 polymorphisms were recently associated to pulmonary em-
physema [129, 168].
In the present study, the SERPINE2 rs729631 SNP and the 
rs729631–rs840088 haplotype were found to be associated with pan-
lobular emphysema; these associations were significant in both of the 
study cohorts. Stratified analysis revealed a two-fold risk for panlobu-
lar emphysema for the homozygous variant genotypes of SERPINE2 
rs729631 SNP, and when only pathological changes were considered, 
the risk increased to as high as four-fold. 
These findings are in agreement with the two previous reports con-
cerning SERPINE2 genotypes and emphysema [129, 168]. Interestingly, 
also the study subjects of the first association study [156] were subse-
quently declared as suffering from emphysema [277].
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The converging results from the three previous reports [129, 156, 
168] and the current study indicate that the disease phenotype behind 
the observed association between SERPINE2 and COPD might in fact 
be structural emphysema. This would also explain the discrepant results 
from some of the earlier studies that were not able to find associations 
between SERPINE2 genotypes and COPD among patients with un-
known emphysema status [165–167]. In this regard, the HRCT evalu-
ation becomes superior over lung function measurements; emphysema 
patients with normal lung function may be missed unless diffusing 
capacity measurements or HRCT are performed.
The role of SERPINE2 polymorphisms in the development of differ-
ent emphysema subtypes has not been assessed before. Hence, the present 
study was the first to demonstrate an association between SERPINE2 
genotypes and panlobular emphysema. Intriguingly, also a deficiency 
of AAT, encoded by the SERPINA1 gene, predisposes to early onset 
emphysema of panlobular type [154]. The role of SERPINA1 in the de-
velopment of emphysema is much more evident than that of SERPINE2; 
AAT has a major role in inactivating neutrophil elastase and in that 
way protecting lung tissue from damage [155], while PN1, the protein 
product of SERPINE2, is known to be mainly involved in coagulation 
and fibrinolysis with trypsin, thrombin, plasmin, and urokinase as the 
major substrates [157, 158]. Recent proteolytic analysis has, however, 
revealed a link between metalloproteinases and PN1; mmP9 has been 
shown to regulate the degradation of PN1 by proteolytic cleavage [278]. 
In the same study, the down-regulation of mmP9 was shown to lead to 
a dramatic accumulation of PN1 in prostate carcinoma cells, and mu-
tations in the SERPINE2 gene near mmP9 cleavage sites were shown 
to make PN1 more resistant to mmP9 dependent degradation [278]. 
Based on the observations in the current study and the outcomes of the 
proteolytic analysis [278], it seems very likely that PN1 has a role in 
inhibiting as yet unidentified protease(s) involved in the development 
of emphysema, especially the panlobular type.
Since tobacco smoke, which is an essential factor in our study, 
increases the number of mmP9 secreting inflammatory cells in the 
airways and lung parenchyma [152], smoking could result in enhanced 
degradation of PN1 leading to accumulation of proteases that break 
down the extracellular matrix. In the case of mutations that increase 
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the expression of SERPINE2 gene or make the protein product more 
resistant to degradation, the actions of these proteases would be more 
efficiently inhibited.
In an attempt to further unravel the ambiguous link between genetic 
variation of SERPINE2 and destruction of lung parenchyma, a microar-
ray database search was undertaken to locate genes that are co-expressed 
with SERPINE2 by using the mADCOW-tool [262]. The genes in the 
resulting list were then classified by the DAVID 6.7 functional annotation 
tool [263]. The most enriched clusters included several genes related to 
glycosylation, extracellular matrix, extracellular region, and cell adhesion 
(data not shown). This supports the working hypothesis that SERPINE2 
may, directly or via interactions with other proteins, be involved in the 
extracellular matrix organization.
The SERPINE2 SNPs examined in the current study are not lo-
cated in the mmP9 cleavage site or in any other functional regions of 
the protein product. Instead, they are intronic variants which have no 
known functional consequences, and which have been selected based on 
previous association studies. The F-SNP program [260], connected to 
the main databases, predicts a role for the rs729631 SNP in transcrip-
tional regulation, but finds no regulatory role for the rs840088 SNP. 
However, by using the eQTL Browser [264], it was possible to identify 
a microarray study associating the rs840088 SNP with the expression 
level of SERPINE2 gene [279]. Although it is still possible that the 
associated SNPs are in linkage with other, yet unidentified functional 
variants in SERPINE2 or in completely different genes, the rs729631 and 
rs840088 SNPs showed tight linkage (r2 > 0.8) only to other SERPINE2 
SNPs (1000 Genomes Population; 1KGP). Hence, these intronic SNPs 
could be considered as potential causal variants modifying the risk for 
pulmonary emphysema.
6.3.2  MMP1, MMP9, and MMP12
mmPs, that are capable of degrading elastin and other matrix macromol-
ecules and thereby participating in the protease-antiprotease balance, have 
been abundantly examined concerning COPD and emphysema [153, 
170]. Animal experiments have shown that overexpression of MMP1 and 
MMP9 predispose to emphysematous changes, and that mice lacking the 
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MMP12 gene were protected from emphysema despite of a long term 
exposure to tobacco smoke [172–174]. 
In the current study, a significant association between the MMP9 
rs3918242 variant T-allele and a lowered proneness to pathological cen-
trilobular emphysema was detected. This is in agreement with a recent 
Korean study which reported that the T-allele was protective against 
COPD [187], but contrasts to some of the earlier findings suggesting 
the T-allele as a risk factor for COPD and emphysema [178, 181, 183]. 
There are also reports failing to find any associations between MMP9 
polymorphisms and COPD and/or lung function [180, 188]. 
In addition to the discrepant observations from the original studies, 
the results from recent meta-analyses concerning MMP9 rs3918242 SNP 
appear quite inconsistent; the first meta-analysis identified an increased 
risk for the variant T-allele, whereas the second analysis found a decreased 
risk of COPD for this allele in ethnically mixed populations, but neither 
of these associations were statistically significant [108, 109]. The most 
recent meta-analysis, in which separate analysis were performed for Cau-
casian and Asian populations, found the T-allele to be a significant risk 
factor for COPD only in Asian populations by using dominant model 
[194]. When all the sub-studies with only healthy smokers as controls 
were included, the risk was even more obvious.
As for the MMP1 and MMP12, no significant associations were de-
tected between their polymorphisms and emphysema or lung function. 
This contrasts with the previous works reporting associations between 
MMP1 and MMP12 polymorphisms and COPD, emphysema, lung 
function, and gas transfer capacity [180, 185, 186, 188, 189]. Similarly 
to the results of the present study, however, some earlier reports have 
failed to associate MMP1 [184, 187, 188] or MMP12 [184, 185, 187] 
to COPD and/or lung function.
The somewhat contradictory results from the MMP association 
studies may partly originate from ethnic differences, lack of power due 
to small sample sizes, or phenotypic heterogeneity of COPD. Other 
unidentified genetic and/or epigenetic factors may also confound the 
association, which makes it hard to clarify the role of MMP9 rs3918242 
SNP and other MMP polymorphisms in the development of pulmonary 
emphysema from the currently existing data.
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In the present study, no associations were observed between the stud-
ied MMP genes and fibrotic changes. Although differential expression 
of mmP1, mmP9, and mmP12 have been implicated in the develop-
ment of fibrotic lung diseases [175, 176], the genetic association studies 
concerning MMPs and fibrosis are scarce; one report has described an 
association between MMP1 promoter polymorphism and IPF [280], but 
no previous association study has examined the MMP polymorphisms 
in relation to asbestos associated non-malignant diseases. Hence, the 
differential expression of mmPs detected in asbestos associated fibrosis 
[171] is probably mainly attributed to other factors than genetic varia-
tion of MMPs.
6.3.3  TIMP2
TImPs are involved in tissue repair and remodeling and protease-anti-
protease balance by binding mmPs and inhibiting their actions [169]. 
TImP2, released by alveolar macrophages, can inhibit most of the mmPs 
including collagenases (mmP1) and gelatinases (mmP9). The TImPs 
have been proposed to play a role in the development of pulmonary 
fibrosis and emphysema [153, 171], and certain TIMP2 polymorphisms 
have been connected to COPD [179, 182].
In the present study, the TIMP2 rs2277698 SNP was found to be 
associated with overall and paraseptal emphysema, FEV1/FVC ratio, 
and mEF50. Stratified analysis revealed a two-fold risk for pathological 
paraseptal changes for individuals with at least one rs2277698 variant 
A-allele. In addition, FEV1/FVC ratio tended to be lower among carriers 
of homozygous variant A-allele genotype, and mEF50 was significantly 
reduced among individuals with at least one variant A-allele.
The rs2277698 SNP is a synonymous base-substitution with uncon-
firmed functional consequences. Although it has previously been specu-
lated to associate with a down-regulation of TImP2 activity leading to 
matrix degradation and COPD [179], this has remained unconfirmed. 
Interestingly, the F-SNP program predicts that rs2277698 SNP is highly 
likely to be involved in splicing regulation [260]. Hypothetically, if the 
A-allele were to create an unstable or incomplete TIMP2 message RNA, 
it would lead to deficient protein product, decreased mmP inhibition, 
and increased matrix degradation. This, again, could explain the pre-
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sent findings indicating that the A-allele was a risk factor for paraseptal 
emphysema and peripheral obstruction (i.e., decreased FEV1/FVC ratio 
and mEF50) typical of smoking related emphysema.
An association was also found between TIMP2 rs2277698 SNP 
and pleural thickenings; the carriage of rs2277698 variant A-allele was 
shown to predispose to high calcification degree of the thickenings. The 
relationship between TImP2 and pleural plaques has not been explored 
before. Instead, results from animal experiments have indicated that the 
over-expression of TImP2 could inhibit the development of atheroscle-
rotic plaques and prevent plaque destabilization [281]. However, the 
mechanisms involved in the development of atherosclerotic plaques are 
probably sufficiently different from the development of pleural plaques 
to allow firm conclusions to be drawn.
There is, however, also the possibility that the causal variant behind 
paraseptal emphysema and peripheral obstruction is not the phenom-
enon studied here; the TIMP2 rs2277698 SNP is in strong linkage (r2 > 
0.8 in 1KGP) with other TIMP2 SNPs, some of which (rs9889410 and 
rs11654470) reside in an area predicted to alter the transcriptional regulation 
[260]. However, in 1KGP, SNPs from other genes are not strongly linked 
to the rs2277698 SNP. Based on these observations and the TImP2 func-
tion, it is very likely that it is involved in the pathogenesis of emphysema. 
6.4  Inflammation and innate immunity   
 related genes
6.4.1  TNF
Both asbestos and tobacco smoke are known to induce TNF secretion 
from alveolar macrophages and other inflammatory cells [8, 11], which, 
in turn, enhances the expression of TGFB1 [196]. Together TNF and 
TGFB1 may provoke immune suppression and lung fibrogenesis, and 
participate in the down-regulation of collagen degradation through 
mmPs and TImPs [197, 198]. TNF gene polymorphisms have previ-
ously been associated with the development of emphysema and asbestosis 
[199, 282], and these have been studied widely also in relation to COPD 
[108, 109, 190, 192, 193].
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In the current study, no associations were found between TNF poly-
morphisms and asbestos related fibrosis. This could be due to phenotypic 
heterogeneity; in the previous study, a strict diagnosis of asbestosis was 
used, whereas in the current study fibrotic changes were used as such. 
In addition, since the control subjects of the previous study were not 
exposed to asbestos, the analyses were not adjusted for asbestos exposure 
level [199].
On the contrary, significant association was observed between the 
TNF rs1800629 SNP and paraseptal emphysema. Further analysis re-
vealed a twofold risk for pathological paraseptal changes for individuals 
with at least one variant A-allele. This finding is in agreement with a 
recent meta-analysis with over 5500 COPD patients and controls [109]. 
However, meta-analyses stratifying the study population based on eth-
nicity seem to suggest that the risk for COPD is statistically significant 
only among Asian subjects [108, 192, 193].
Another insight supporting our finding is that the rs1800629 vari-
ant A-allele has been associated with enhanced TNF expression [283], 
which, in turn has been shown to induce emphysematous changes in 
mouse models [203, 284]. The possible mechanism explaining the as-
sociation between TNF and paraseptal type of emphysema, however, 
remains to be clarified.
6.4.2  TGFB1
The TGFB1 polymorphisms have previously been associated with as-
bestosis and emphysema [200, 205, 206], and several meta-analyses 
investigating the relationship between TGFB1 and COPD have been 
performed [108, 109, 191].
In the present study, TGFB1 rs2241718 SNP and a haplotype consist-
ing of the rs1800469 and rs1800470 SNPs were found to be associated 
to centrilobular emphysema. Stratified analysis showed that the variant 
A-allele in rs2241718 locus and a haplotype consisting of rs1800469 
variant A-allele and rs1800470 wild-type T-allele were protective against 
pathological centrilobular changes. Together with the MMP9 rs3918242 
variant T-allele the TGFB1 rs2241718 variant A-allele reduced the risk 
of pathological centrilobular emphysema into fifth compared to the 
wild-type genotype.
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The results from recent meta-analyses concerning the rs1800469 
and rs1800470 SNPs and COPD are somewhat divergent; in two meta-
analyses [108, 109] the variant allele of rs1800470 SNP was found to 
protect from COPD in ethnically mixed populations, while a third 
meta-analysis [191] failed to detect any effects for this allele. Conversely, 
in the third meta-analysis, the variant allele of rs1800469 was shown 
to increase the risk of COPD among Asian populations, while the two 
other meta-analyses failed to see any effect for it in mixed populations. 
We also found the rs2241718 SNP to be associated with asbestos 
induced visceral pleural fibrosis, and two TGFB1 haplotypes consisting 
of rs1800469 and rs1800470 SNPs to be associated with pleural plaque 
calcification. In stratified analysis, the variant allele of TGFB1 rs2241718 
SNP was found to confer protection against visceral pleural fibrosis. 
The TGFB1 rs2241718 SNP is located in the non-coding area near 
to the gene and there are no known functional consequences for this 
polymorphism. The promoter-area SNP (rs1800469) is in tight linkage 
with the third studied signal peptide SNP (rs1800470, Leu10Pro; for-
merly known as rs1982073), which has been associated with increased 
secretion and higher serum levels of TGFB1 [285, 286]. moreover, the 
F-SNP program predicts that the rs1800470 SNP might be involved in 
splicing regulation [260]. 
It is also possible that the causative variant resides outside the TGFB1 
gene; the studied TGFB1 SNPs are in tight linkage with polymorphisms 
in e.g., TMEM91, HNRNPUL1, and B9D2 genes (r2 > 0.9 in 1KGP). 
However, since TGFB1 is a down-stream effector of NLRP3 mediated 
innate immunity response, and also involved in the regulation of protease-
antiprotease balance, it could be speculated to play a role in the patho-
genesis of lung diseases related to external exposure and inflammation. 
Both TGFB1 and mmP9, genetic polymorphisms of which were 
found protective against centrilobular emphysema in the present study, 
can be secreted from Ams. Ams, in turn, are activated by cigarette smoke 
and found in increased numbers in airways and lung parenchyma of 
COPD patients [152]. Since centrilobular emphysema is the most com-
mon type of pulmonary emphysema and closely associated to cigarette 
smoke [86, 287], the effects of TGFB1 and MMP9 polymorphisms in 
the development of centrilobular disease could be mediated through 
macrophages via an interaction with cigarette smoke.
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6.4.3  NLRP3 and CARD8
There is growing evidence that inflammasomes are involved in the 
pathogenesis of chronic respiratory disorders, and there is also increas-
ing interest in examining how the genes of innate immunity are related 
to these diseases [288]. The NLRP3 inflammasome complex, consisting 
of several components including NLRP3, PYCARD, and CARD8, can 
be activated by asbestos leading to IL-1β secretion [28]. This complex 
has been proposed to play a role in the development of fibrotic diseases 
[289], but so far, very few data exists on the association of inflammasome 
complex genes and pulmonary fibrosis.
The current study revealed a significant association between NLRP3 
rs35829419 SNP and asbestos induced interstitial lung fibrosis; the 
carriage of at least one variant A-allele was found to pose almost a 2.5-
fold risk for pathological fibrotic changes compared to individuals with 
the wild type genotype. moreover, a truncating polymorphism (C10X; 
rs2043211) in another member of the complex, CARD8, was associated 
with the greatest thickness of pleural plaques. 
Both rs35829419 and rs2043211 SNPs have previously been linked 
to increased IL-1β production and severe inflammation [207]. The 
rs35829419 SNP changes amino acid (Q705K) in the NLRP3 protein, 
and there is recent evidence to suggest that it is a gain-of-function muta-
tion leading to constantly active NLRP3 inflammasome and increased 
IL-1β levels [290]. This, again, may induce fibrosis and is therefore in 
agreement with our findings. 
Interestingly, there is a recent study pointing to an association between 
the variant T-allele of another NLRP3 SNP (rs1539019) and coal work-
ers´ pneumoconiosis (CWP) [291]. CWP is a lethal fibrotic lung disease 
induced by inhalation of airborne coal mining dust, including crystalline 
silica [32]. Although the functional consequences of the rs1539019 SNP 
are not known, this finding is in agreement with the present results and 
strengthens the hypothesis of the involvement of the NLRP3 inflamma-
some complex in the development of fibrotic lung diseases.
The role of NLRP3 inflammasome complex has also been implicated 
in the development of COPD [292], but genetic association studies sup-
porting this view are lacking to date. The current study did not discover 
any new evidence concerning the NLRP3 inflammasome genes and 
pulmonary emphysema.
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6.4.4  GC
GC is a multifunctional serum protein, which is known to participate 
in several immunologically important functions such as macrophage 
activation [208]. GC has been proposed to be involved in the chronic 
inflammation process of the lungs, and its gene polymorphisms have 
been extensively studied in several pulmonary disorders [209]. There 
are three common variants (haplotypes) in the GC gene (GC1F, GC1S, 
and GC2), due to the presence of two SNPs (rs4588 and rs7041), that 
affect the function of the protein [208]. These haplotypes and SNPs 
have been repeatedly associated with COPD and impairment of lung 
function [210–219].
In the current study, no significant associations were observed between 
GC SNPs (rs4588 and rs7041) or haplotypes and emphysema, fibrosis, 
pleural plaques, or lung function parameters. There are many potential 
explanations for this discrepancy; first, most of the previous studies were 
rather small, with 100 COPD patients or less [210–216], and in two of 
the most recent larger studies utilizing replication cohorts, only a few 
associations could actually be replicated [218, 219]. Second, there may be 
some confounding factors related to vitamin D that should be accounted 
for when studying GC. Third, including the present study, there are no 
reports associating GC with pulmonary emphysema; hence, it is possible 
that GC does not contribute to the emphysema phenotype of COPD.
6.5  strengths and weaknesses of  
 the present study
In the current study, two cohorts of asbestos exposed construction 
workers were combined and used in a case-control setting to examine 
the role of selected candidate gene polymorphisms in the development 
of different pleural, pulmonary, and lung function changes related to 
asbestos and tobacco smoke exposure. 
One of the main strengths of the present study is the carefully char-
acterized population; because lung function and CT-findings (interstitial 
and visceral pleural fibrosis, pleural plaques, and emphysema subtypes) 
were recorded separately and classified according to their severity, there 
104
6 discussion
was the possibility to examine the genetic background of very finely 
defined phenotypes.
Another advantage is that the present patient material was consider-
ably large and a lot of ex- and current smokers were included. This is 
useful in demonstrating the genetic predisposition to emphysema, which 
probably would not have manifested to such a marked degree without 
smoking.
This study also has some potential limitations. First, since the patients 
were enrolled in three cities during two separate primary studies, four 
different CT-scanners were used and seven radiologists participated in 
the image assessment. However, since the Finnish population is very 
homogenous and the three cities, where the patients were enrolled, 
are all located in southern Finland very close to each other, it seems 
most unlikely that the geographic origin would be responsible for any 
significant bias appearing in the data analysis. moreover, any inconsist-
ency in image reading or in the technical image quality could cause an 
inaccuracy, i.e., random noise added to the results which would lead to 
a loss of power rather than to a systematic error. This increases the error 
variance in computations and the detected associations are therefore 
likely to be underestimated.
Second, in addition to asbestos and tobacco smoke, it is most likely 
that the study subjects have also been occupationally exposed to other 
particles, such as concrete, silica, and wood dusts, and these could well 
have contributed to the development of pulmonary diseases. Unfortu-
nately information about exposure data of these dusts was not available 
from our study subjects. 
Finally, the multiple comparisons performed increase the possibility of 
detecting false-positive associations. However, no corrections were used 
since most of the methods which attempt to correct for multiple testing 
are very conservative, and it is not even clear what could be considered as 
the correct number of comparisons for which one should adjust [293]. 
Nonetheless, the present results should be considered with caution until 
replicated in an independent study population.
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7  conclusions
In this thesis, the roles of several genes involved in xenobiotic metabo-
lism, protease-antiprotease balance, innate immunity, and inflammation 
were studied in the development of different asbestos and tobacco smoke 
exposure related pleural and pulmonary changes, peripheral obstruction, 
and impairment of pulmonary diffusing capacity. 
According to the present results, polymorphisms of certain XmE 
genes are potential modifiers of the risk of developing pleural and pul-
monary changes related to asbestos and tobacco smoke exposure. The 
most convincing evidence came from GSTT1; the deletion of this gene 
was significantly associated with several types of changes in the whole 
study population and in both of the study cohorts separately. Thus, one 
could speculate that GSTT1 has a crucial role in the metabolism of dif-
ferent kind of environmental agents entering the lungs.
Another principal observation was the association between serine 
protease inhibitor SERPINE2 and panlobular emphysema. Together 
with the findings concerning MMP9, TIMP2, TNF, and TGFB1, this 
implies that polymorphisms of genes involved in protease-antiprotease 
balance likely contribute to the development of pulmonary emphysema 
and bronchial obstruction, and different molecular mechanisms may 
explain the development of different emphysema subtypes.
The present results also indicate that genetic variation in innate 
immunity related genes may have an important role in coping with as-
bestos exposure. One very interesting finding supporting this view was 
the association between interstitial lung fibrosis and polymorphism of 
NLRP3, an essential component of the NLRP3 inflammasome complex. 
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This study is a typical example of candidate gene approach, where 
prior knowledge of the function of the gene is coupled to the current 
understanding of the pathogenesis of the phenotype of interest [294]. 
Unfortunately, candidate gene studies have not produced very repeat-
able results, as discussed above in relation to the genes investigated here. 
Candidate genes are usually examined in a case-control setting, where 
study size is critical in order to obtain reproducible results. many of the 
earlier studies have been performed in rather small populations leading 
to a lack of statistical power, which may partly explain the conflicting 
results of the literature. The inconsistencies could also be due to genetic 
heterogeneity and complexity; most often the disease phenotype is the 
outcome of multiple genetic and/or epigenetic factors that interact with 
the environment. 
Another important source of error is the phenotypic heterogeneity; 
in the case of COPD, for example, it has become evident that a more 
accurate patient characterization is needed in order to clarify the mo-
lecular mechanisms and genetic factors behind different phenotypes, and 
ultimately, to develop more effective therapies for this disorder [80, 81].
New genome-wide applications are increasingly used in identifying 
the genomic regions associated with complex diseases. Although GWA 
studies are hypothesis-free and considered as unbiased, similarly to the 
situation with other association studies, they are confronted with many 
statistical and methodological problems such as disease misclassification, 
population stratification, genotyping errors, and statistical significance 
due to multiple comparisons [295, 296]. 
The advent of next generation sequencing (NGS) technologies has, 
in turn, lowered the costs of direct sequencing; these are now attractive 
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options for investigating the genetic variation associated with human 
diseases. Compared to the other technologies, sequencing offers the 
benefit that it can identify all sequence variants in an individual genome, 
exome, or sub-genomic area of interest [294]. 
Despite the new technological advances, candidate gene and case-
control strategies are still needed to confirm and define the results ob-
tained from genome-wide applications. However, if one hopes to conduct 
a reliable replication, the quality of candidate gene studies needs to be 
considerably improved. Based on the current study and the previous 
literature, one of the key factors in this process is the rigorous charac-
terization of patients and controls in order to create homogeneous study 
populations. It has also been proposed that more stringent significance 
thresholds and independent replication cohorts should be used [297].
Since biological systems are complex and cannot be predicted by their 
single constituents, more than genetic association studies are needed if 
one hopes to obtain a better understanding of the human diseasome. 
A call for systems biology approach integrating functional genomics, 
transcriptomics, proteomics, and metabolomics by the means of bio-
informatics has been expressed also in the field of pulmonary research, 
and the first steps have been taken in identifying the functional and 
regulatory pathways that play central roles in respiratory pathophysiol-
ogy [298, 299]. After the primary causes and mechanisms of a disease 
development start to emerge, it is possible not only to diagnose and treat 
patients more efficiently, but also to identify people at-risk or individuals 
who would be especially vulnerable to certain environmental exposures.
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Both tobacco smoke and asbestos fibers enter the body mainly by 
inhalation. In the lungs, they may evoke oxidative stress, alter the 
protease-antiprotease balance, induce innate and adaptive immune 
responses, and create persistent inflammation leading eventually to 
lung injury. The type and severity of lung injury induced by foreign 
compounds varies greatly between individuals, even with similar 
exposure history. These differences are believed to originate from 
the complex interplay between genetic, epigenetic, environmental, 
and life course factors.
In this study, the effects of genetic variation on the risk and severity 
of asbestos and smoking related non-malignant pleural and pulmo-
nary changes and lung function impairment was examined among 
Finnish construction workers. The studied polymorphic genes 
encode proteins involved in xenobiotic metabolizing, proteolytic 
balance, inflammation, and innate immunity; pathways that are 
potentially linked to asbestos and tobacco smoke exposure. 
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